Zeo ScientifiX (ZEOX) 10-K 7 Jul 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Oct. 31, 2016	Jul. 07, 2017	Apr. 29, 2016
Document And Entity Information
Entity Registrant Name	Biotech Products Services & Research, Inc.
Entity Central Index Key	1,557,376
Document Type	10-K
Document Period End Date	Oct. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 723,724
Entity Common Stock, Shares Outstanding		111,464,982
Trading Symbol	BPSR
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Oct. 31, 2016	Oct. 31, 2015
Current Assets
Cash	$ 26,223	$ 37,565
Accounts receivable	1,125	19,878
Inventories	9,944
Prepaid expenses		4,163
Assets attributable to discontinued operations		89,353
Total Current Assets	37,292	150,959
Property and equipment, net	27,606	1,638
Security deposits	5,000
TOTAL ASSETS	69,898	152,597
Current Liabilities
Accounts payable and accrued expenses	248,847	105,324
Accrued liabilities to management	378,274
Accounts payable related party		9,354
Deferred revenue		15,000
Notes payable	100,000
Advances from CEO		300
Liabilities attributable to discontinued operations	125,851	9,771
Total Liabilities	852,972	139,749
Commitments and contingencies
Stockholders' Equity (Deficit)
Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.001 par value, 750,000,000 shares authorized; 104,214,982 and 99,198,114 shares issued and outstanding, respectively	104,215	99,198
Additional paid-in capital	1,226,322	774,060
Accumulated deficit	(2,113,611)	(860,410)
Total Stockholders' Equity (Deficit)	(783,074)	12,848
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 69,898	$ 152,597

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Oct. 31, 2016	Oct. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	104,214,982	99,198,114
Common stock, shares outstanding	104,214,982	99,198,114

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Oct. 31, 2016	Oct. 31, 2015
Income Statement [Abstract]
Revenues	$ 184,881	$ 147,629
Cost of revenues	94,402	49,411
Gross profit	90,479	98,218
General and administrative expenses	1,133,796	842,527
Loss from operations	(1,043,317)	(744,309)
Other income (expense) – interest expense	(12,729)
Loss from continuing operations	(1,056,046)	(744,309)
(Loss) income from discontinued operations	(197,155)	5,955
Net loss	$ (1,253,201)	$ (738,354)
Net loss per common share - basic and diluted:
Continuing operations	$ (0.01)	$ (0.01)
Discontinued operations	0	0
Total	$ (0.01)	$ (0.01)
Weighted average number of common shares outstanding - basic and diluted	100,377,159	134,047,251

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Oct. 31, 2016	Oct. 31, 2015
Statement of Comprehensive Income [Abstract]
Net Loss	$ (1,253,201)	$ (738,354)
Change in currency translation adjustments		(2,795)
Total Comprehensive Loss	$ (1,253,201)	$ (741,149)

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Total
Balance at Oct. 31, 2014	$ 150,120	$ (83,120)	$ 2,795	$ (122,056)	$ (52,261)
Balance, shares at Oct. 31, 2014	150,120,000
Forgiveness of related party loan		42,058			42,058
Cancellation of common stock	$ (60,120)	60,120
Cancellation of common stock, shares	(60,120,000)
Stock compensation	$ 4,590	263,410			268,000
Stock compensation, shares	4,590,000
Sale of common stock	$ 4,608	491,592			496,200
Sale of common stock, shares	4,608,114
Currency translation adjustments			(2,795)		(2,795)
Net loss				(738,354)	(738,354)
Balance at Oct. 31, 2015	$ 99,198	774,060		(860,410)	12,848
Balance, shares at Oct. 31, 2015	99,198,114
Sale of common stock	$ 5,017	452,262			457,279
Sale of common stock, shares	5,016,868
Net loss				(1,253,201)	(1,253,201)
Balance at Oct. 31, 2016	$ 104,215	$ 1,226,332		$ (2,113,611)	$ (783,074)
Balance, shares at Oct. 31, 2016	104,214,982

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Oct. 31, 2016	Oct. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (1,253,201)	$ (738,354)
Net income (loss) from discontinued operations	(197,155)	5,955
Net loss from continuing operations	(1,056,046)	(744,309)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	345	86
Bad debt expense	500
Stock-based compensation		268,000
Changes in operating assets and liabilities:
Accounts receivable	18,253	(19,878)
Prepaid expenses	4,163	(4,163)
Inventories	(9,944)
Security deposits	(5,000)
Accounts payable and accrued expenses	143,523	105,324
Accrued liabilities to management	378,274
Accounts payable – related party	(9,354)	9,354
Deferred revenue	(15,000)	15,000
Net cash used in operating activities – continuing operations	(550,286)	(370,586)
Net cash provided by (used in) operating activities - discontinued operations	2,098	(75,935)
Net cash used in operating activities	(548,188)	(446,521)
CASH FLOWS FROM INVESTING
Purchase of fixed assets	(26,313)	(1,724)
Net cash used in investing activities – continuing operations	(26,313)	(1,724)
Net cash provided by (used in) investing activities – discontinued operations	6,180	(6,180)
Net cash used in investing activities	(20,133)	(7,904)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from advances from CEO		300
Repayments on advances from CEO	(300)
Proceeds from issuance of notes payable	100,000
Proceeds from sale of common stock and warrants	457,279	496,200
Net cash provided by financing activities – continuing operations	556,979	496,500
Net cash used in financing activities – discontinued operations		(4,754)
Net cash provided by financing activities	556,979	491,746
Increase (decrease) in cash	(11,342)	37,321
Cash at beginning of year	37,565	244
Cash at end of year	26,223	37,565
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for taxes
Cash paid for interest
NON-CASH INVESTING AND FINANCING TRANSACTIONS:
Cancellation of common shares		60,120
Forgiveness of advances from director		$ 42,508

Organization and Description of

Organization and Description of Business	12 Months Ended
	Oct. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Biotech Products Services and Research, Inc. (formerly Bespoke Tricycles Inc.) (“BPSR” or the “Company”) was incorporated on August 9, 2011 in the State of Nevada. On May 29, 2015, Albert Mitrani acquired controlling interest of BPSR through the purchase of 135,000,000 shares of common stock from John Goodhew and subsequently became a director and the sole officer of BPSR. Until October 30, 2015, the Company’s business included the designing, manufacturing, and selling vending tricycles for commercial customers. On October 30, 2015, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with John Goodhew, the Company’s director, pursuant to which all of the shares of Bespoke Tricycles, Ltd. (“Bespoke”), a corporation organized under the Laws of England and Wales, were transferred to Mr. Goodhew. As a result of such sale, the Company was no longer in the business of designing, manufacturing, and selling vending tricycles. The purchase price for the shares sold to Mr. Goodhew was $10. The results of Bespoke are reflected as discontinued operations in the financial statements. Since the change in control of our Company in June 2015 and change in the Company’s operations in July 2015, the Company has been engaged in the health care industry, principally focusing on supplying products and services related to the growing field of regenerative anti-aging medicine. For the fiscal year ended October 31, 2016, the Company operated through the following wholly owned subsidiaries: Beyond Cells Corp., a Florida corporation (“Beyond Cells”) formed with a business purpose to provide anti-aging and cellular therapy patient marketing and product sales; General Surgical of Florida, Inc., a Florida corporation (“General Surgical”) with a business purpose to sell cellular therapy products to doctors and hospitals; and Ethan New York, Inc., a New York corporation (“Ethan NY”) formed with a business purpose of selling clothing and accessories through a retail store. Ethan NY operations were closed during June 2016 and the results of Ethan NY are reflected as discontinued operations in the financial statements. During August 2016, the Company formed Anu Life Sciences, Inc. (“ANU”), a Florida corporation and a wholly owned subsidiary of the Company with a business purpose of the development, production and manufacturing of anti-aging and cellular therapy products. ANU began operations during November 2016 and commenced sales of its first product offering during February 2017. During February 2017, the Company established Mint Organics, Inc. (“Mint Organics”) a Florida corporation and a 55%-owned subsidiary of the Company with a business purpose of operating Medical Marijuana Treatment Centers (“MMTC”) for defined MMTC licensed activities. During February 2017, the Company established Mint Organics Florida, Inc., (“Mint Organics Florida”), a Florida corporations and a wholly owned subsidiary of Mint Organics with a business purpose of operating Medical Marijuana Treatment Centers (“MMTC”) for defined MMTC licensed activities within Florida. Subsequent to the formation of Mint Organics and Mint Organics Florida, both entities have issued minority non-voting equity interests.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Oct. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Reclassifications Certain prior year amounts have been reclassified to conform with the current financial statement presentation including adjusted footnotes to reflect the presentation of discontinued operations as further discussed in Note 13. Concentrations of Credit Risk The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $250,000 per institution. At October 31, 2016, we did not have any cash balances in financial institutions in excess of FDIC insurance coverage. During the fiscal year ended October 31, 2016, one customer accounted for approximately $27,000 or 14.5% of revenues. During the fiscal year ended October 31, 2016, we purchased products from one supplier totaling approximately $53,000 or 56.0% of our cost of revenues. The Company’s sales and supply agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products and/or the availability of products from other suppliers. Since February 2017, the Company commenced the manufacturing and distribution of proprietary products that will further reduce exposure by increasing its ability to sell to customers and eliminate reliance on third party suppliers. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates. Accounts Receivable Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. For the year ended October 31, 2016 and 2015, the Company recorded bad debt expense of $500 and $0. Inventory Inventory is stated at the lower of cost or market using the average cost method. The Company regularly reviews inventory quantities on hand to identify slow-moving merchandise and markdowns necessary to clear slow-moving merchandise. Estimates of markdown requirements may differ from actual results due to changes in quantity, quality and mix of products in inventory, as well as changes in consumer preferences, market and economic conditions. Property and Equipment Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of property and equipment range from 3 to 5 years. Upon sale or retirement, the cost and related accumulated depreciation and amortization are eliminated from their respective accounts, and the resulting gain or loss is included in results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. Revenue Recognition The Company recognizes revenue on arrangements in accordance with FASB ASC Topic. 605 “Revenue Recognition”. In all cases, revenue is recognized only when the price is fixed and determinable, persuasive evidence of an arrangement exists, the service is performed and collectability of the resulting receivable is reasonably assured. Net Income (Loss) Per Common Share Basic income (loss) per common share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. At October 31, 2016, the Company had 1,737,479 common shares issuable upon the exercise of warrants that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the year ended October 31, 2016. At October 31, 2015, the Company had 1,008,114 common shares issuable upon the exercise of warrants that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the year ended October 31, 2015. Stock-Based Compensation All stock-based payments to employees, including grants of employee stock options, are recognized in the financial statements based on their fair values. Stock options and warrants issued to consultants and other non-employees as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can be more clearly determined. Foreign Currency Translation The functional currency of Bespoke was British pounds and was translated to U.S. dollars using the exchange rate effective for the date reported for assets and liabilities and the average exchange rate for the period reported for revenues and expenses. Fair Value of Financial Instruments The Company follows FASB ASC 820, Fair Value Measurement, which clarifies fair value as an exit price, establishes a hierarchal disclosure framework for measuring fair value, and requires extended disclosures about fair value measurements. The provisions of ASC 820 apply to all financial assets and liabilities measured at fair value. As defined in ASC 820, fair value, clarified as an exit price, represents the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a result, fair value is a market-based approach that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering these assumptions, ASC 820 defines a three-tier value hierarchy that prioritizes the inputs used in the valuation methodologies in measuring fair value. Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Subsequent Events The Company has evaluated subsequent events that occurred after October 31, 2016 through the financial statement issuance date for subsequent event disclosure consideration. New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014- 09, “Revenue from Contracts with Customers (Topic 606).” The new guidance provides new criteria for recognizing revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new guidance requires expanded disclosures to provide greater insight into both revenue that has been recognized and revenue that is expected to be recognized in the future from existing contracts. Quantitative and qualitative information will be provided about the significant judgments and changes in those judgments that management made to determine the revenue that is recorded. This accounting standard update, as amended, will be effective for annual reporting periods beginning after December 15, 2018, and interim reporting periods within annual reporting periods beginning after December 15, 2019. The new revenue standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. Early adoption is permitted, but no earlier than fiscal 2017. The Company is currently assessing the provisions of the guidance and has not determined the impact of the adoption of this guidance on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The new standard requires management to assess the company’s ability to continue as a going concern. Disclosures are required if there is substantial doubt as to the company’s continuation as a going concern within one year after the issue date of financial statements. The standard provides guidance for making the assessment, including consideration of management’s plans which may alleviate doubt regarding the Company’s ability to continue as a going concern. ASU 2014-15 is effective for years ending after December 15, 2016. Early adoption is permitted. The Company has adopted this standard for the year ending October 31, 2016, and management has concluded that there is substantial doubt as to the Company’s continuation as a going concern within one year after the issue date of the financial statements. In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is currently evaluating the impact of the new pronouncement on its financial statements. In April 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation” (topic 718). The FASB issued this update to improve the accounting for employee share-based payments and affect all organizations that issue sharebased payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The updated guidance is effective for annual periods beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption of the update is permitted. The Company adopted this guidance in the first quarter of 2017. The adoption of this update had no material effect on the Company’s financial position or results of operations. The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Going Concern

Going Concern	12 Months Ended
	Oct. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 3 – GOING CONCERN The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has had limited revenues since its inception. The Company incurred a net loss of $1,253,201 for the year ended October 31, 2016. In addition, the Company had an accumulated deficit of $2,113,611 at October 31, 2016. The Company had a negative working capital position of $851,680 at October 31, 2016. The Company’s efforts to establish a stabilized source of sufficient revenues to cover operating costs has yet to be achieved and ultimately may prove to be unsuccessful unless additional sources of working capital through operations or debt and/or equity financings are realized. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management anticipates that the Company will remain dependent, for the near future, on additional investment capital to fund ongoing operating expenses. All of the Company’s assets are currently pledged in connection with the SPA and as a result does not have any assets to pledge for the purpose of borrowing additional capital. The Company’s current market capitalization and common stock liquidity will hinder its ability to raise equity proceeds. The Company anticipates that future sources of funding, if any, will therefore be costly and dilutive. if available at all. In view of the matters described in the preceding paragraphs, recoverability of the recorded asset amounts shown in the accompanying consolidated balance sheet assumes that (1) the Company will be able to establish a stabilized source of revenues, (2) obligations to the Company’s creditors are not accelerated, (3) the Company’s operating expenses remain at current levels and/or the Company is successful in restructuring and/or deferring ongoing obligations, (4) the Company obtains additional working capital to meet its contractual commitments and maintain the current level of Company operations through debt or equity sources. There is no assurance that the Company will be able to complete its revenue growth strategy or otherwise obtain sufficient working capital to cover ongoing cash requirements. Without sufficient cash reserves, the Company’s ability to pursue growth objectives will be adversely impacted. Furthermore, despite significant effort since July 2015, the Company has thus far been unsuccessful in achieving a stabilized source of revenues. If revenues do not increase and stabilize or if additional funds cannot otherwise be raised, the Company might be required to seek other alternatives which could include the sale of assets, closure of operations and/or protection under the U.S. bankruptcy laws.

Inventories

Inventories	12 Months Ended
	Oct. 31, 2016
Inventory Disclosure [Abstract]
Inventories	NOTE 4 – INVENTORIES Inventories totaled $9,944 and $0 at October 31, 2016 and October 31, 2015, respectively. ANU inventory was associated with materials acquired for the manufacturing of products to be sold in 2017. October 31, 2016 October 31, 2015 ANU materials $ 9,944 $ - Total Inventories $ 9,944 $ -

Property and Equipment

Property and Equipment	12 Months Ended
	Oct. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 5 - PROPERTY AND EQUIPMENT October 31, 2016 October 31, 2015 Computer equipment $ 1,724 $ 1,724 Manufacturing equipment 26,313 - 28,037 1,724 Less: accumulated depreciation and amortization (431 ) (86 ) Total property and equipment, net $ 27,606 $ 1,638 Depreciation expense of property, plant and equipment from operations totaled $345 and $86 for the years ended October 31, 2016 and 2015, respectively.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Oct. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 6 – RELATED PARTY TRANSACTIONS During the year ended October 31, 2015, a former Director of the Company was reimbursed by the Company $4,604, and the former Director also forgave $42,058 of advances to the Company. The Company classified the forgiveness as a capital contribution. During the fiscal year ended October 31, 2015, the Company recorded salary expense to its Chief Executive Officer (“CEO”) in the amount of $118,846, of which $88,039 was paid through October 31, 2015. The Company also recorded salary and consulting fees to the CEO’s wife in the amount of $78,773, of which $69,419 was paid through October 31, 2015. In addition, the Company also made payments on behalf of the CEO and the CEO’s wife for health benefit costs and automobile related allowances totaling approximately $11,281 for the fiscal year ended October 31, 2015. During the fiscal year ended October 31, 2016, the Company recorded salary expense to its CEO in the amount of $241,845, of which $91,845 was paid through October 31, 2016. The Company also recorded salary and consulting fees to the CEO’s Wife in the amount of $138,729, of which $33,896 was paid through October 31, 2016. Expenses of approximately $44,000 were reimbursed in relation to the consulting service. In addition, the Company also made payments on behalf of the CEO and the CEO’s wife for health benefit costs and automobile related allowances totaling approximately $46,868 for the fiscal year ended October 31, 2016. As described below, as of October 31, 2016, the Company recorded an aggregate of $150,000 and $104,833 of accrued salary related expenses owed to the CEO and the CEO’s wife, respectively, for all advances, loans, consulting fees and/or salary related compensation owed to each of the CEO and/or CEO’s wife through October 31, 2016. Prior to November 4, 2016, the CEO and the CEO’s wife did not have employment agreements or consulting agreements with the Company and had agreed to defer any future salary or consulting payments based on availability of cash resources of the Company. Effective November 4, 2016, the Company entered into executive employment agreements with Albert Mitrani, the CEO; the CEO’s wife Maria Mitrani, the Chief Science Officer (“CSO”); Bruce Werber, the Chief Operating Officer (“COO”); and Ian Bothwell, the Chief Financial Officer (“CFO”). On March 8, 2017, the Company entered into an executive employment agreement with Terrell Suddarth, the Chief Technology Officer (“CTO”), and amended the CSO’s, the COO’s and CFO’s executive employment agreements (collectively the CEO, CSO, COO, CFO’s and CTO’s executive employment agreements, as amended, are referred to as the “Executive Agreements”). In connection with the executive employment agreements with the CEO and the CSO, the Company agreed to pay the CEO and the CSO a total of $150,000 and $104,833, respectively, representing the total amount of all advances, loans, consulting fees and/or salary related compensation owing to each of the CEO and the CSO up through November 4, 2016. The payment of the above amounts is to be paid in the future based on the available cash of the Company. See Note 11 for a more detailed description of the Executive Agreements. Effective August 1, 2016, the Company’s corporate administrative offices were moved to office space in Miami Beach, Florida. The office space is leased from MariLuna, LLC, a Florida limited liability company which is owned by the CSO. The term of the lease is 24 months and the monthly rent is $2,500. The Company paid a security deposit of $5,000. In connection with the executive employment agreement between the Company and the CFO, the Company agreed to reimburse Rover Advanced Technologies, LLC, a company owned and controlled by the CFO for office rent and other direct expenses (phone, internet, copier and direct administrative fees, etc.) up to a maximum of $2,500 per month. As of October 31, 2016 the CFO and COO, were owed approximately $70,000 and $53,000, respectively, by the Company for advances and unreimbursed expenses in connection with the Company’s operations during the fiscal year ended October 31, 2016. As of March 29, 2017, the CFO and COO, were owed approximately $150,000 and $150,000, respectively, by the Company for advances and unreimbursed expenses in connection with the Company’s operations through March 29, 2017. On March 29, 2017, in connection with the SPA (see Note 7), the advances and unreimbursed expenses owed to the CFO and COO totaling $300,000 were converted and made part of the initial Tranche funding amounts as provided for in the SPA. As a result of the conversion, the advances and unreimbursed expenses are now secured obligations of the Company, and shall be payable, convertible into common shares of the Company and secured in accordance with the terms of the SPA. On March 29, 2017, in connection with the terms of the SPA, the CFO and the COO were each granted 1,000,000 common shares of the Company valued at $31,790. On November 1, 2016, the Company issued 100 shares of Series A Non-Convertible Preferred Stock, par value $0.001 per share (“Series A Preferred Stock”) to the CEO. On March 8, 2017, the Company issued 100 shares of the Series A Preferred Stock, to each the COO, CSO and CFO. The Series A Preferred Stock shall vote together with the shares of common stock and other voting securities of the Company as a single class and such shares shall represent 80% of all votes entitled to be voted at any annual or special meeting of stockholders of the Company or action by written consent of stockholders. The Company determined that the value attributable to the Series A Preferred Stock issued were nominal. On March 8, 2017, Mint Organics, Inc. issued warrants to the CEO, CSO and CFO to each purchase 79 shares of the Class A Common Stock, of Mint Organics, Inc., vesting on the date Mint Organics, Inc., through one of its subsidiaries, obtains a license from any state to dispense cannabis until the fifth anniversary thereof at an exercise price of $0.001 per share. On February 14, 2017, Mr. Peter Taddeo and Mr. Wayne Rohrbaugh each invested $150,000 in the Company in connection with the Company’s endeavor, through Mint Organics, Inc., to obtain a license to dispense medical cannabis in Florida. In consideration for their investment, on February 28, 2017, Mr. Taddeo and Mr. Rohrbaugh were each issued 150 shares of Series A Preferred Stock of Mint Organics, Inc. and a warrant from the Company to purchase up to 150,000 shares of common stock of the Company for $0.15 per share exercisable from the date of issuance of the warrant until the third anniversary date of the date of issuance. Mr. Taddeo was also appointed as the Chief Executive Officer and as a director of Mint Organics, Inc. and Mint Organics Florida, Inc. Mr. Rohrbaugh was also appointed as the Chief Operating Officer and as a director of Mint Organics, Inc. and Mint Organics Florida, Inc. The Series A Preferred Stock, as more fully described in Note 12, is convertible into Class B common stock of Mint Organics, Inc. or into common stock of the Company. During February 2017, the Company sold 250,000 shares of common stock to the COO’s daughter at $0.04 per share for an aggregate purchase price of $10,000 based on the closing price of the common stock of the Company on the date the stock was issued. On May 17, 2017, Mint Organics entered into an executive employment agreement with Peter Taddeo, the CEO of Mint Organics (the “Taddeo Agreement”). In connection with the Taddeo Agreement, the Company granted Taddeo 1,000,000 shares of unregistered restricted Common Stock valued at $0.012 per share, the closing price of the Common Stock of the Company on the date of grant. The shares vest on the date Mint Organics, through one of its subsidiaries, obtains a license from a state to dispense cannabis or December 31, 2017, whichever is earlier, and provided that Taddeo’s employment has not been terminated prior to the time the vesting conditions have been met. See Note 12 for a more detailed description of the Taddeo Agreement. Certain of the Company’s customers are related and/or affiliated with employees and/or consultants of the Company. For the year ended October 31, 2016, the total amount of sales to customers related to employees and/or consultants of the Company totaled $15,703.

Notes Payable

Notes Payable	12 Months Ended
	Oct. 31, 2016
Debt Disclosure [Abstract]
Notes Payable	NOTE 7 — NOTES PAYABLE On November 12, 2015, the Company entered into an unsecured loan agreement (“$15,000 Note Payable”) with an unaffiliated lender pursuant to which the Company received proceeds of $15,000. The $15,000 Note Payable bears interest at 8% per annum compounded annually and was due one year after the date of issuance. On April 3, 2017, in connection with the SPA, the $15,000 Note Payable plus accrued interest was fully paid (see below). On December 24, 2015, the Company entered into an unsecured loan agreement (“$50,000 Note Payable”) with an unaffiliated lender pursuant to which the Company received proceeds of $50,000. The $50,000 Note Payable bears interest at 8% per annum compounded annually and was due one year after the date of issuance. On April 3, 2017, in connection with the SPA, the $50,000 Note Payable plus accrued interest was fully paid (see below). On April 27, 2016, the Company entered into an unsecured loan agreement (“$35,000 Note Payable”) with a consultant of the Company pursuant to which the Company received proceeds of $35,000. The payoff amount of the $35,000 Note Payable was $42,000 and was due on May 31, 2016 (an annualized interest rate of approximately 221%). On April 3, 2017, in connection with the SPA, the $35,000 Note Payable plus accrued interest was fully paid (see below). SPA - Convertible Promissory Note On March 29, 2017, the Company entered into a Securities Purchase Agreement, dated March 29, 2017 (“SPA”), with an unaffiliated “accredited investor” (“Agent”), Dr. Bruce Werber, the Company’s Chief Operating Officer and a member of the Board of Directors of the Company (“Werber”), and Ian T. Bothwell, the Company’s Chief Financial Officer and member of the Board of Directors (“Bothwell”) (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). The transactions contemplated by the SPA were consummated on April 3, 2017. Purchase and Sale Pursuant to the SPA, the Purchasers shall be entitled to purchase a 10% Original Issue Discount Convertible Secured Promissory Note and Guarantee in the principal amount of up to $1,666,667, corresponding to a subscription amount of up to $1,500,000 (“Note”). The purchase of the Note is to occur in several tranches (each a “Tranche”) pursuant to the terms and conditions of the SPA. In connection with the terms of the SPA, the Purchasers agreed to subscribe to the initial Tranche through the second Tranche for an amount in the aggregate of up to $600,000 (subject to adjustment as described the SPA) corresponding to an aggregate of up to $666,667 in principal amount of the Note. The initial Tranche of $475,000 (which correlates to a principal amount of $527,778 of the Note) was consummated on the closing of the SPA, of which an aggregate of $300,000 (which correlates to a principal amount of $333,333 of the Note) was funded through the rollover of unreimbursed advances and expenses made to the Company by Werber and Bothwell prior to the closing date of the SPA and the remaining $175,000 was funded at Closing by the Agent. The second Tranche will be for $125,000 ($138,889 in principal amount of the Note) and will be funded to the Company by the Agent on July 15, 2017, subject to certain conditions contained in the SPA. Subject to the acceleration and/or prepayment provisions as provided for in the SPA, all unpaid principal, fees and accrued and unpaid interest of the Note shall be due and payable in full on March 31, 2018. The unpaid principal amount of the Note shall accrue interest at 10% per annum, provided that upon the occurrence and during the continuance of an event of default as defined in the SPA, the outstanding principal amount of this Note and any accrued and unpaid interest and all other overdue amounts shall each bear interest until paid at the rate of 18% per annum. Additionally, in the event that the publicly traded price of the common stock falls below $0.0125 for 3 consecutive trading days, then the Note shall accrue interest at the default interest rate. During the period April 27, 2017 to May 1, 2017, the closing price of the common stock fell below $0.0125 and accordingly beginning May 2, 2017, the default interest rate of 18% is in effect. Accrued interest shall be payable commencing on June 30, 2017, and continuing on the last business day of each subsequent calendar quarter. In the event of a conversion of this Note prior to the maturity date, all accrued and unpaid interest shall be added to the principal amount being converted as of the date of conversion to determine the amount of securities into which the Note shall be converted. In connection with the terms of the SPA, the Company issued the Agent, Werber and Bothwell a total of 2,000,000, 1,000,000 and 1,000,000 common shares of the Company (“Commitment Shares”), respectively, valued in the aggregate at $63,580, based on the closing price of the Common Stock of the Company on the date the stock was issued. The Note may be prepaid by the Company at any time, provided however that any prepayment amount will be subject to a prepayment penalty of 20% to 40% based on the date that the prepayment is made. At any time after the six (6) month anniversary of the closing date and until this Note is no longer outstanding, any outstanding principal portion of this Note shall be convertible, in whole or in part, into shares of common stock of the Company at the option of each Purchaser (subject to the conversion limitations set forth in the SPA). The conversion price in effect on any conversion date shall be equal to the lower of (i) $0.15, and (ii) 60% of the lowest daily volume weighed average price in the 20 trading days prior to the conversion date. Under the terms of the SPA, Bothwell and Werber are not eligible to convert their portion of the Note until the Agent has been fully repaid. According to the SPA, the Purchasers may fund the Company in different Subscription Amounts at each closing after the second Tranche and are not required to participate in each such subsequent Tranche. In the event that any Purchaser does not participate in any Tranche after the second Tranche, the remaining Purchasers shall have the right to participate in such Tranche in an amount up to 100% of the entire Tranche. In the event that such participating Purchasers do not collectively fund 100% of the desired Tranche amount, then the Company shall be permitted to request from any Person (as defined in the SPA) the remaining amount, so long as such Person(s) agree to execute the SPA (and further, the Company and the Purchasers agree to amend the Agreement and the Note as necessary). The Company is not obligated to consummate any additional Tranche fundings subsequent to the second Tranche. The SPA contained customary representations, warranties and covenants for similar transactions by the Company and Purchasers, including restrictions on incurrence of future indebtedness and/or issuance of equity. In addition, included in the covenants was a covenant made by the Company to be up to date with all of its filings with the Securities and Exchange Commission (“SEC”) by July 15, 2017, including without limitation, all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Exchange Act of 1934, as amended (“Exchange Act”). The Company used the proceeds received at closing from the initial Tranche for general working capital purposes and the repayment of all outstanding obligations owing in connection with the $15,000 Note Payable, the $50,000 Note Payable and the $35,000 Note Payable. In connection with the SPA, the Company will record an original issue discount consisting of the discount in the aggregate cash received at closing, the intrinsic value of the Commitment Shares and any underlying value attributable to the fair value of the embedded derivatives liabilities associated with the Notes at the issuance date based on an independent valuation using a Monte Carlo Model (the Notes contain full ratchet reset provisions and variable market based conversion derivative features). The Company will record the amount of the derivative liabilities at the time of closing as a reduction of the remaining initial carrying amount of the Notes and the excess amount after reducing the initial carrying amount of the Note to $0, if any, as a charge to the income statement. The derivative liability will be marked-to-market each quarter with the change in fair value recorded in the income statement. Unamortized discount is amortized to interest expense using the effective interest method over the life of the Note. Security Agreement As an inducement for the Agent to fund the Company, on March 29, 2017, the Company and its subsidiaries: ANU; General Surgical Beyond Cells; BD Source and Distribution, Corp., a Florida corporation; Ethan New York; Mint Organics, Inc., and Mint Organics Florida, (each a “Subsidiary” or “Guarantor” and together, the “Guarantors”) entered into a Security Agreement, dated March 29, 2017 (the “ Security Agreement “), with the Agent, whereby BPSR and each Subsidiary granted the Agent a perfected, first priority security interest in and to all of their respective tangible and intangible assets, whether presently owned or existing or hereafter acquired or coming into existence and all proceeds therefrom, and including the capital stock of each Guarantor. In addition, upon the full satisfaction of the obligations owing to the Agent, all other Purchasers (excluding the Agent) shall assume the security rights of the Agent described above until all of their respective amounts owed by the Company have been fully repaid. Intellectual Property Security Agreement On March 29, 2017, BPSR and the Guarantors entered into an Intellectual Property Security Agreement (the “IP Security Agreement”) with the Agent, whereby BPSR and each Guarantor granted the Agent a perfected, first priority security interest in and to all of their respective intellectual property. Subsidiary Guarantee On March 29, 2017, the Subsidiaries entered into a Subsidiary Guarantee (the “Subsidiary Guarantee”) in favor of the Agent. Pursuant to the Subsidiary Guarantee, the Subsidiaries, jointly and severally, unconditionally and irrevocably, guaranteed the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the obligations of the Company to the Agent and its respective successors, endorsees, transferees and assigns under the Subsidiary Guarantee, the Note and Intellectual Property Security Agreement and any documents executed and delivered in connection therewith.

Income Taxes

Income Taxes	12 Months Ended
	Oct. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 8 — INCOME TAXES The Company is required to file a consolidated tax return that includes all of its subsidiaries. For the fiscal years ended October 31, 2016 and 2015, the Company has incurred operating losses, and therefore, there were not any tax expense amounts recorded during those years. The cumulative net operating loss carry-forward is approximately $1,845,000 and will expire beginning in 2031. A reconciliation of the U.S. federal statutory tax amount to the Company’s effective tax amount is as follows: Year Ended October 31, 2016 Year Ended October 31, 2015 Income tax benefit at statutory rate (34%) $ (426,088 ) $ (251,040 ) Stock-based compensation - 91,120 Valuation allowance 426,088 159,920 Total $ - $ - The tax effects of temporary differences and carry-forwards that give rise to deferred tax assets and liabilities for the Company were as follows: October 31, 2016 October 31, 2015 Deferred tax asset attributable to: Net operating loss carry-forward $ 627,507 $ 201,419 Less valuation allowance (627,507 ) (201,419 ) Total $ - $ - The ultimate realization of deferred tax assets depends on various factors including the generation of taxable income in future periods. The Company has concluded that the future sources of taxable income do not assure the realization of 100% of the deferred tax assets. Therefore, the Company has recorded a valuation allowance in the amount of 100% of the deferred tax assets due to the uncertainty of realizing the deferred tax assets.

Capital Stock

Capital Stock	12 Months Ended
	Oct. 31, 2016
Equity [Abstract]
Capital Stock	NOTE 9 – CAPITAL STOCK Preferred Stock The Company is authorized to issue 10,000,000 shares of $0.001 par value preferred stock in one or more designated series, each of which shall be so designated as to distinguish the shares of each series of preferred stock from the shares of all other series and classes. The Company’s board of directors is authorized, without stockholders’ approval, within any limitations prescribed by law and the Company’s Articles of Incorporation, to fix and determine the designations, rights, qualifications, preferences, limitations and terms of the shares of any series of preferred stock. Series A Non-Convertible Preferred Stock On November 1, 2016, the Company filed a Certificate of Designation with the Secretary of State of Nevada therein designating out of the 10,000,000 authorized shares of Preferred Stock, a class of Preferred Stock as “Series A Non-Convertible Preferred Stock” consisting of 100 shares (the “ Series A Certificate of Designation “). On March 2, 2017, the Company filed with the Secretary of State of Nevada an amendment to increase the number of shares provided for in the Series A Certificate of Designation from 100 shares to 400 shares. Set forth below is a summary of the Series A Certificate of Designation, as amended. Voting Generally, the outstanding shares of Series A Non-Convertible Preferred Stock shall vote together with the shares of Common Stock and other voting securities of the Company as a single class and, regardless of the number of shares of Series A Non-Convertible Preferred Stock outstanding, and as long as at least one share of Series A Non-Convertible Preferred Stock is outstanding, such shares shall represent eighty percent (80%) of all votes entitled to be voted at any annual or special meeting of stockholders of the Company or action by written consent of stockholders. Each outstanding share of the Series A Non-Convertible Preferred Stock shall represent its proportionate share of the 80% which is allocated to the outstanding shares of Series A Non-Convertible Preferred Stock. Dividends The holders of shares of Series A Non-Convertible Preferred Stock shall not be entitled to receive any dividends. Ranking The Series A Non-Convertible Preferred Stock shall, with respect to distribution rights on liquidation, winding up and dissolution, (i) rank senior to any of the shares of Common Stock of the Company, and any other class or series of stock of the Company which by its terms shall rank junior to the Series A Non-Convertible Preferred Stock, and (ii) rank junior to any other series or class of preferred stock of the Company and any other class or series of stock of the Company which by its term shall rank senior to the Series A Non-Convertible Preferred Stock. So long as any shares of Series A Non-Convertible Preferred Stock are outstanding, the Company shall not alter or change any of the powers, preferences, privileges or rights of the Series A Non-Convertible Preferred Stock, without first obtaining the approval by vote or written consent, in the manner provided by law, of the holders of at least a majority of the outstanding shares of Series A Non-Convertible Preferred Stock, as to changes affecting the Series A Non-Convertible Preferred Stock. Issued Shares On November 1, 2016, the Company issued 100 shares of its Series A Non-Convertible Preferred Stock, par value $0.001 per share (“Series A Preferred Stock”) to the CEO. On March 8, 2017, the Company issued 100 shares of the Series A Preferred Stock, to each of the COO, CSO and CFO. Series B Convertible Preferred Stock On November 1, 2016, the Company filed a Certificate of Designation with the Secretary of State of Nevada therein designating out of the 10,000,000 authorized shares of Preferred Stock, a class of Preferred Stock as “Series B Convertible Preferred Stock” consisting of 1,000,000 shares (“Series B Certificate of Designation”). Set forth below is a summary of the Series B Certificate of Designation. Conversion Each holder of Series B Preferred Stock shall have the right, at such holder’s option, at any time or from time to time from and after the day immediately following the date the Series B Preferred Stock is first issued, to convert each share of Series B Preferred Stock into 20 fully-paid and non-assessable share of Common Stock. Rank Except as specifically provided below, the Series B Preferred Stock shall, with respect to dividend rights, rights on liquidation, winding up and dissolution, rank junior to the Series A Non-Convertible Preferred Stock of the Company and senior to (i) all classes of Common Stock of the Company and (ii) any class or series of capital stock of the Company hereafter created (unless, with the consent of the holder(s) of Series B Preferred Stock). Issued Shares There are currently no shares of Series B Convertible Preferred Stock outstanding as of the filing date of this report on Form 10-K for the year ended October 31, 2016. Common Stock The Company is authorized to issue up to 250,000,000 shares of common stock, $0.001 par value per share. On September 17, 2015, the Company completed an eighteen-for-one forward stock split. The consolidated financial statements and notes reflect a retroactive adjustment for the forward stock split. On June 6, 2017, the Board of Directors of the Company and the stockholders holding the Company’s outstanding Series A Preferred Stock, having the voting equivalency of 80% of the outstanding capital stock, approved the filing of an amendment to the Articles of Incorporation of the Company to increase the authorized amount of Common Stock from 250,000,000 to 750,000,000, without changing the par value of the Common Stock or authorized number and par value of “blank check” Preferred Stock. On June 19, 2017, the Company filed a Definitive 14C with the SEC regarding the corporate action. On June 22, 2017, the Company filed a Certificate of Amendment to the Company’s Articles of Incorporation with the Secretary of State of Nevada to effectuate the corporate action on July 10, 2017. Sales of Common Stock On February 19, 2015, the Company sold 1,800,000 shares of common stock in a private placement for total cash proceeds of $25,000. On May 28, 2015, the Company sold 1,800,000 shares of common stock for total cash proceeds of $25,000. From June 11, 2015 through September 2, 2015, the Company sold an aggregate of 311,200 Units to various third parties. Each Unit cost $1.00 and consisted of two shares of common stock, one Class A Warrant and one Class B Warrant. The Company issued 622,400 shares of common stock, Class A warrants to purchase 311,200 common shares and Class B warrants to purchase 311,200 common shares. The Class A Warrant and Class B warrant have exercise prices of $0.50 and $1.00, respectively, and have a four-year term. The aggregate grant date fair value of the warrants issued in connection with this offering was $91,263. On July 9, 2015, the Company’s Chief Executive Officer and the Company cancelled 60,120,000 shares of common stock previously held by the Company’s Chief Executive Officer. From August 2015 to October 2015, the Company sold 192,857 Units to various investors. Each Unit cost $0.70 and consisted of two shares of common stock, one Class A Warrant and One Class B Warrant. The Company issued 385,714 shares, Class A warrants to purchase 192,857 common shares and Class B warrants to purchase 192,857 common shares. The Class A Warrant and Class B warrant have exercise prices of $0.50 and $1.00, respectively, and have a four-year term. The aggregate grant date fair value of the warrants issued in connection with this offering was $83,060. During September 2015, the Company issued 4,590,000 shares of common stock to a consultant of the Company. The Company recorded $268,000 of stock-based compensation expense based on the grant date fair value of these shares. During the year ended October 31, 2015, a Director forgave $42,058 of advances to the Company. The Company recorded the forgiveness of $42,058 as a capital contribution to the Company. From November 2015 to March 2016, the Company sold an aggregate of 364,685 Units to 9 “accredited investors”. Each Unit cost $0.70 and consisted of two shares of common stock, one Class A Warrant and one Class B Warrant. The Company issued a total of 729,370 shares, Class A warrants to purchase 364,685 common shares and Class B warrants to purchase 364,685 common shares for total proceeds of $255,279. The Class A Warrant and Class B Warrant have exercise prices of $0.50 and $1.00, respectively, and have a four-year term. The grant date fair value of the warrants issued in connection with this offering was $379,893. During April 2016, the Company sold 25,000 shares of common stock to an individual for cash proceeds of $5,000. During July 2016, the Company sold 2,200,000 shares of common stock to investors for cash proceeds of $92,000 (net of $18,000 in offering costs). During August 2016, the Company sold 62,500 shares of common stock to an “accredited investor” at $0.08 per share for an aggregate purchase price of $5,000. During September 2016, the Company sold 2,000,000 shares of common stock to an “accredited investor” at $0.05 per share for an aggregate purchase price of $100,000. During January 2017, the Company sold 100,000 shares of common stock to an “accredited investor” at $0.05 per share for an aggregate purchase price of $5,000. From January 2017 to February 2017, the Company sold an aggregate of 900,000 Units. Each Unit cost $0.10 and consisted of two shares of common stock, one Class A Warrant and one Class B Warrant. The Company issued a total of 1,800,000 shares, Class A warrants to purchase 900,000 common shares and Class B warrants to purchase 900,000, common shares for total proceeds of $90,000. The Class A Warrant and Class B Warrant have exercise prices of $0.075 and $0.150, respectively, and have a three-year term. The aggregate grant date fair value of the warrants issued in connection with this offering was $33,480. During February 2017, the Company sold 250,000 shares of common stock to a related party at $0.04 per share for an aggregate purchase price of $10,000. On March 8, 2017, in consideration for consulting services rendered to the Company and Mint Organics, Inc., the Board approved the issuance of 100,000 shares of unregistered common stock valued at $0.02 per share, the closing price of the common stock of the Company on the date hereof, to a consultant. The Company recorded $2,000 of stock-based compensation expense based on the grant date fair value of these shares. On March 29, 2017, in connection with the terms of the SPA, the Company issued the Agent, Werber and Bothwell a total of 2,000,000, 1,000,000 and 1,000,000 common shares of the Company, respectively, valued in the aggregate at $63,580, based on the closing price of the common stock of the Company on the date the stock was issued. On May 17, 2017, in connection with the Taddeo Agreement, the Company granted Taddeo 1,000,000 shares of unregistered Common Stock valued at $0.012 per share ($12,000), the closing price of the Common Stock of the Company on the date of grant. The shares vest on the date Mint Organics, through one of its subsidiaries, obtains a license from a state to dispense cannabis or December 31, 2017, whichever is earlier, and provided that Taddeo’s employment has not been terminated prior to the time the vesting conditions have been met.

Warrants

Warrants	12 Months Ended
	Oct. 31, 2016
Warrants
Warrants	NOTE 10 – WARRANTS During the year ended October 31, 2015, the Company issued 1,008,114 warrants in connection with common stock offerings and valued the warrants on the dates of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate 1.50% to 1.74%, (2) term of 4 years, (3) expected stock volatility of 100%, and (4) expected dividend rate of 0%. All of the warrants vested immediately. The grant date fair value of the warrants issued during the year ended October 31, 2015 was $174,323. During the year ended October 31, 2016, the Company issued 729,370 warrants in connection with common stock offerings and valued the warrants on the dates of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate from 1.22% to 1.57%, (2) term of 4 years, (3) expected stock volatility from 97% to 100%, and (4) expected dividend rate of 0%. All of the warrants vested immediately. The grant date fair value of the warrants issued during the year ended October 31, 2016 was $379,893. In connection with the Executive Employments Agreements dated November 4, 2016 (see Note 11), the Company granted the following warrants to each executive as described below: Bothwell: a warrant to purchase, on a cashless basis, up to 31,800,000 shares of common stock of the Company for $0.06 per share, the closing price of the Company’s common stock on the date of the grant, exercisable in accordance with the vesting schedule below until the 10th anniversary of the date of issuance: (a) Immediately on the Effective Date, 50% of the Warrant shall vest and the remaining 50% shall vest in 18 equal monthly installments beginning on November 30, 2016 or until Bothwell no longer remains employed by the Company, whichever is earlier. Notwithstanding the foregoing vesting schedule, the unvested portion of the Warrant shall be accelerated upon the achievement of the milestones set forth below, to the satisfaction of the Board in its sole discretion and contingent upon Mr. Bothwell’s continued employment at the time of consummation: 1. 25% upon the consummation of an equity or debt financing and resulting in gross proceeds of at least $300,000, including, but not limited to, the currently contemplated financing in connection with the SPA; and 2. 25% upon the consummation of a series of equity or debt financings resulting in aggregate process gross proceeds in excess of $1,500,000. The Company valued the above warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate of 1.79%, (2) term of 10 years, (3) expected stock volatility of 152%, and (4) expected dividend rate of 0%. The grant date fair value of the warrants issued was $1,879,380 and such costs will be expensed prorata as the warrants vest. Werber: a warrant to purchase, on a cashless basis, up to 31,800,000 shares of common stock of the Company for $0.06 per share, the closing price of the Company’s common stock on the date of the grant, fully vested at the time of the grant and exercisable until the 10th anniversary of the date of issuance. The Company valued the above warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate of 1.79%, (2) term of 10 years, (3) expected stock volatility of 152%, and (4) expected dividend rate of 0%. The grant date fair value of the warrants issued was $1,879,380 and such costs will be expensed prorata as the warrants vest. M. Mitrani: a warrant to purchase, on a cashless basis, up to 10,000,000 shares of common stock of the Company for $0.06 per share, the closing price of the Company’s common stock on the date of the grant, fully vested at the time of the grant and exercisable until the 10th anniversary of the date of issuance. The Company valued the above warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate of 1.79%, (2) term of 10 years, (3) expected stock volatility of 152%, and (4) expected dividend rate of 0%. The grant date fair value of the warrants issued was $591,000 and such costs will be expensed prorata as the warrants vest. During January 2017 and February 2017, the Company issued 1,800,000 warrants in connection with common stock offerings and valued the warrants on the dates of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate 1.43% to 1.45%, (2) term of 3 years, (3) expected stock volatility of 106%, and (4) expected dividend rate of 0%. All of the warrants vested immediately. The grant date fair value of the warrants issued was $33,480. In connection with the Participation Agreement, on March 8, 2017, the Company issued warrants to Mr. Peter Taddeo, a member of the Board and the Chief Executive Officer and a director of both Mint Organics and Mint Organics Florida and Mr. Wayne Rohrbaugh, the Chief Operating Officer and a director of both Mint Organics and Mint Organics Florida, to each purchase 150,000 shares of common stock of the Company at an exercise price of $0.15 per share, exercisable from the date of issuance until the third anniversary date of the date of issuance. The Company valued the above warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate of 1.38%, (2) term of 3 years, (3) expected stock volatility of 106%, and (4) expected dividend rate of 0%. The grant date fair value of the warrants issued was $4,770. On March 8, 2017, in connection with Mr. Suddarth’s employment agreement, the Company granted Mr. Suddarth a warrant to purchase, on a cashless basis, 23,850,000 shares of the Company’s common stock at an exercise price of $0.02 per share, the closing price of common stock of the Company on March 8, 2017, exercisable in accordance with the vesting schedule below until the 10 th (a) Immediately on the Effective Date, 50% of the Warrant shall vest and, thereafter, the remaining 50% shall vest in 18 equal monthly installments beginning on March 31, 2017 or until Suddarth no longer remains employed by the Company, whichever is earlier. (b) Notwithstanding the foregoing vesting schedule, the unvested portion of the Warrant shall be accelerated upon the achievement of the milestones set forth below, to the satisfaction of the Board in its sole discretion and contingent upon Mr. Suddarth’s continued employment at the time of consummation: 1. 25% for the commercial availability of a sheet type human amnion product 2. 15% for the third commercially available product; and 3. 10% for the fourth commercially available product The Company valued the above warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate of 2.57%, (2) term of 10 years, (3) expected stock volatility of 153%, and (4) expected dividend rate of 0%. The grant date fair value of the warrants issued was $469,845 and such costs will be expensed prorata as the warrants vest. On March 8, 2017, the Board of the Company granted warrants to purchase shares of common stock of the Company on a cashless basis to the following executive officers and directors of the Company: Executive Officer Warrants: Dr. Bruce Werber (Chief Operating Officer and Director) 21,500,000 Ian T. Bothwell (Chief Financial Officer and Director) 21,500,000 Dr. Maria Ines Mitrani (Chief Science Officer and Director) 13,850,000 TOTAL 56,850,000 The foregoing warrants are exercisable for $0.02 per share, the closing price of Common Stock of the Company on March 8, 2017, and are exercisable from the date of issuance until the 10th anniversary of the date of issuance. The Company valued the above warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate of 2.57%, (2) term of 10 years, (3) expected stock volatility of 153%, and (4) expected dividend rate of 0%. The grant date fair value of the warrants issued was $1,119,945 and such costs will be expensed prorata as the warrants vest. A summary of warrant activity for the years ended October 31, 2015 and 2016 are presented below. Number of Shares Weighted-average Exercise Price Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at October 31, 2014 - $ - Granted 1,008,114 $ 0.75 4.00 $ - Exercised - $ - Expired/Forfeited - $ - Outstanding and exercisable at October 31, 2015 1,008,114 $ 0.75 3.78 $ - Number of Shares Weighted-average Exercise Price Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at October 31, 2015 1,008,114 $ 0.75 3.78 $ - Granted 729,370 $ 0.75 4.00 $ - Exercised - $ - Expired/Forfeited - $ - Outstanding and exercisable at October 31, 2016 1,737,484 $ 0.75 3.01 $ -

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Oct. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 11 – COMMITMENTS AND CONTINGENCIES On June 22, 2015, the Company entered into an agreement with a consultant whereby the Company agreed to issue the consultant a warrant to purchase shares of common stock for up to 4.9% of the outstanding common stock of the Company. The terms of the warrant agreement were not determined or authorized by the Board of Directors of the Company, and accordingly, the warrant obligation has not been recorded by the Company. Employment Agreements On August 1, 2015, the Company entered into employment agreements with two employees. Each employment agreement contained the following terms: (a) if net monthly sales generated by the Company are less than $50,000 and net profit margin on the aggregate sales is less than 35%, no Base Salary is payable; (b) if net monthly sales generated by the Company are $50,000 or more but less than $75,000 and net profit margin on the aggregate sales is less than 35%, the Base Salary shall be $6,000; (b) if net monthly sales generated by the Company are $75,000 or more but less than $100,000 and net profit margin on the aggregate sales is less than 35%, the Base Salary shall be $9,000; and (d) if net monthly sales generated by the Company are $100,000 or more and net profit margin on the aggregate sales is less than 35%, the Base Salary shall be $15,000. In addition, the Company agreed to issue each employee 225,000 restricted shares of common stock of the Company upon achieving certain milestones. On November 17, 2015, the Company executed a Termination Agreement and Mutual Release in connection with both of the above-mentioned employment agreements. The parties released each other from any claims or liabilities one to the other, and the employment agreements between the Company and each of the employees were terminated in their entirety. The Company was not required to issue any of the shares of common stock provided for in the agreements or make any settlement payments in connection with the terminations. Executive Employment Agreements Albert Mitrani On November 4, 2016, the Company entered into an executive employment agreement, (“A. Mitrani Agreement”) effective November 4, 2016, with Albert Mitrani (“A. Mitrani”), pursuant to which A. Mitrani agreed to continue to serve as the Company’s Chief Executive Officer and Chairman of the Board of Directors of the Company for the term of the A. Mitrani Agreement, subject to state and federal law and the bylaws of the Company, as long as A. Mitrani beneficially owns at least 3% of the common stock of the Company. Below is a summary of the material terms of the A. Mitrani Agreement: Term The employment term shall continue until the fifth anniversary thereof, unless terminated earlier pursuant to the terms of the A. Mitrani Agreement; provided that, on such fifth anniversary of the effective date and each fifth anniversary thereafter, the A. Mitrani Agreement shall be deemed to be automatically extended, upon the same terms and conditions, for successive periods of five years, unless either party provides written notice of its intention not to extend the term of the A. Mitrani Agreement at least 90 days prior to the applicable renewal date. Base Salary A. Mitrani’s base annual salary is $360,000, which shall accrue commencing October 1, 2016 and shall be payable upon the Company generating sufficient net revenue or obtaining sufficient third party financing; and thereafter payable in periodic installments in accordance with the Company’s customary payroll practices, but no less frequently than monthly. The base salary shall be reviewed at least annually by the Board and the Board may, but shall not be required to, increase the base salary during the employment term. Annual and Signing Bonus A. Mitrani is eligible to receive an annual bonus, as established by the Board and based on established performance milestones being achieved. In connection with the execution of the A. Mitrani Agreement, the Company agreed to pay A. Mitrani a $100,000 signing bonus which shall be accrued and paid by the Company upon the Company having sufficient cash flow. Past Due Amounts As of the effective date, A. Mitrani and/or his affiliates were owed for unpaid expenses, salary and consulting fees of approximately $120,000. The past due amounts shall be paid upon the earliest reasonable practicable time that there is sufficient working capital as determined by the Board. Dr. Bruce Werber On November 4, 2016, and amended March 8, 2017, the Company entered into an executive employment agreement, (“Werber Agreement”) effective November 4, 2016, with Dr. Bruce Werber (“Werber”), pursuant to which the Company appointed Werber as the Chief Operating Officer (“COO”) of the Company and the Chief Executive Officer of ANU and General Surgical. Pursuant to the Werber Agreement, the Company agreed to appoint Werber as a member of the board of directors of the Company for the term of the Werber Agreement, subject to state and federal law and the bylaws of the Company, as long as Werber beneficially owns at least 3% of the common stock of the Company. Below is a summary of the material terms of the Werber Agreement: Term The employment term shall continue until the third anniversary thereof, unless terminated earlier pursuant to the terms of the Werber Agreement; provided that, on such third anniversary of the effective date and each annual anniversary thereafter, the Werber Agreement shall be deemed to be automatically extended, upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term of the Werber Agreement at least 90 days’ prior to the applicable renewal date. Base Salary Werber’s base annual salary is $360,000, which shall accrue commencing October 1, 2016 and shall be payable upon the Company generating sufficient net revenue or obtaining sufficient third party financing; and thereafter payable in periodic installments in accordance with the Company’s customary payroll practices, but no less frequently than monthly. The base salary shall be reviewed at least annually by the Board and the Board may, but shall not be required to, increase the base salary during the employment term. Annual and Signing Bonus Werber is eligible to receive an annual bonus, as established by the Board and based on established performance milestones being achieved. In connection with the execution of the Werber Agreement, the Company agreed to pay Werber a $35,000 signing bonus which shall be accrued and paid by the Company upon the Company having sufficient cash flow. Warrant In connection with the execution of the Werber Agreement, the Company granted Werber a warrant to purchase, on a cashless basis, up to 31,800,000 shares of common stock of the Company for $0.06 per share, the closing price of the Company’s common stock on the Effective Date, fully vested at the time of the grant and exercisable until the 10th anniversary of the date of issuance. Dr. Maria Ines Mitrani On November 4, 2016, and amended March 8, 2017, the Company entered into an executive employment agreement, (“M. Mitrani Agreement”) effective November 4, 2016, with Dr. Maria Ines Mitrani (“M. Mitrani”), pursuant to which the Company appointed M. Mitrani as the Chief Science Officer (“CSO”) of the Company. Pursuant to the M. Mitrani Agreement, the Company agreed to appoint M. Mitrani as a member of the board of directors of the Company for the term of the M. Mitrani Agreement, subject to state and federal law and the bylaws of the Company, as long as M. Mitrani beneficially owns at least 3% of the common stock of the Company. Below is a summary of the material terms of the M. Mitrani Agreement: Term The employment term shall continue until the fifth anniversary thereof, unless terminated earlier pursuant to the terms of the M. Mitrani Agreement; provided that, on such fifth anniversary of the effective date and each fifth anniversary thereafter, the M. Mitrani Agreement shall be deemed to be automatically extended, upon the same terms and conditions, for successive periods of five years, unless either party provides written notice of its intention not to extend the term of the M. Mitrani Agreement at least 90 days’ prior to the applicable renewal date. Base Salary M. Mitrani’s base annual salary is $250,000, which shall accrue commencing October 1, 2016 and shall be payable upon the Company generating sufficient net revenue or obtaining sufficient third party financing; and thereafter payable in periodic installments in accordance with the Company’s customary payroll practices, but no less frequently than monthly. The base salary shall be reviewed at least annually by the Board and the Board may, but shall not be required to, increase the base salary during the employment term. In connection with the amendment of the M. Mitrani Agreement on March 8, 2017, M. Mitrani’s base annual salary was increased to $300,000. Annual and Signing Bonus M. Mitrani is eligible to receive an annual bonus, as established by the Board and based on established performance milestones being achieved. In connection with the execution of the M. Mitrani Agreement, the Company agreed to pay M. Mitrani a $50,000 signing bonus which shall be accrued and paid by the Company upon the Company having sufficient cash flow. Past Due Amounts As of the effective date, M. Mitrani and/or her affiliates were owed for unpaid expenses and consulting fees of approximately $84,000. The past due amounts shall be paid upon the earliest reasonable practicable time that there is sufficient working capital as determined by the Board. Warrant In connection with the execution of the M. Mitrani Agreement, the Company granted M. Mitrani a warrant to purchase, on a cashless basis, up to 10,000,000 shares of common stock of the Company for $0.06 per share, the closing price of the Company’s common stock on the Effective Date, fully vested at the time of the grant and exercisable until the 10th anniversary of the date of issuance. Ian T. Bothwell On November 4, 2016, and amended March 8, 2017, the Company entered into an executive employment agreement, (“Bothwell Agreement”) effective November 4, 2016, with Ian T. Bothwell (“Bothwell”), pursuant to which the Company appointed Bothwell as the Chief Financial Officer (“CFO”) of the Company. Pursuant to the Bothwell Agreement, the Company agreed to appoint Bothwell as a member of the board of directors of the Company for the term of the Bothwell Agreement, subject to state and federal law and the bylaws of the Company, as long as Bothwell beneficially owns at least 3% of the common stock of the Company. Below is a summary of the material terms of the Bothwell Agreement: Term The employment term shall continue until the third anniversary thereof, unless terminated earlier pursuant to the terms of the Bothwell Agreement; provided that, on such third anniversary of the effective date and each annual anniversary thereafter, the Bothwell Agreement shall be deemed to be automatically extended, upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term of the Bothwell Agreement at least 90 days’ prior to the applicable renewal date. Base Salary Bothwell’s base annual salary is $360,000, which shall accrue commencing October 1, 2016 and shall be payable upon the Company generating sufficient net revenue or obtaining sufficient third party financing; and thereafter payable in periodic installments in accordance with the Company’s customary payroll practices, but no less frequently than monthly. The base salary shall be reviewed at least annually by the Board and the Board may, but shall not be required to, increase the base salary during the employment term. Annual and Signing Bonus Bothwell is eligible to receive an annual bonus, as established by the Board and based on established performance milestones being achieved. In connection with the execution of the Bothwell Agreement, the Company agreed to pay Bothwell a $35,000 signing bonus which shall be accrued and paid by the Company upon the Company having sufficient cash flow. Warrant In connection with the execution of the Bothwell Agreement, the Company agreed to issue Bothwell a warrant to purchase, on a cashless basis, up to 31,800,000 shares of common stock of the Company for $0.06 per share, the closing price of the Company’s common stock on the Effective Date, exercisable in accordance with the vesting schedule below until the 10th anniversary of the date of issuance (“Bothwell Warrant”): Immediately on the effective date, 50% of the Bothwell Warrant shall vest and the remaining 50% shall vest in 18 equal monthly installments beginning on November 30, 2016 or until Bothwell no longer remains employed by the Company, whichever is earlier. Notwithstanding the foregoing vesting schedule, the unvested portion of the Bothwell Warrant shall be accelerated upon the achievement of the milestones set forth below, to the satisfaction of the Board in its sole discretion and contingent upon Bothwell’s continued employment at the time of consummation: a) 25% upon the consummation of an equity or debt financing subsequent to the effective date and resulting in gross proceeds of at least $300,000, including, but not limited to, the financing obtained in connection with the SPA; and b) 25% upon the consummation of a series of equity or debt financings subsequent to the effective date resulting in aggregate gross proceeds to the Company in excess of $1,500,000. Terrell Suddarth The Company entered into an executive employment agreement, (“Suddarth Agreement”) effective March 8, 2017, with Terrell Suddarth (“Suddarth”), pursuant to which the Company appointed Suddarth as the Chief Technology Officer (“CTO”) of the Company. Pursuant to the Suddarth Agreement, the Company agreed to appoint Suddarth as a member of the board of directors of the Company for the term of the Suddarth Agreement, subject to state and federal law and the bylaws of the Company, as long as Suddarth beneficially owns at least 3% of the common stock of the Company. Below is a summary of the material terms of the Suddarth Agreement: Term The employment term shall be effective on effective date and shall continue until the third anniversary thereof, unless terminated earlier pursuant to the terms of the Suddarth Agreement; provided that, on such third anniversary of the effective date and each annual anniversary thereafter, the Suddarth Employment Agreement shall be deemed to be automatically extended, upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term of the Suddarth Agreement at least 90 days’ prior to the applicable renewal date. Base Salary Suddarth’s base annual salary is $300,000, which shall accrue commencing on the effective date and shall be payable upon the Company generating sufficient net revenue or obtaining sufficient third party financing; and thereafter payable in periodic installments in accordance with the Company’s customary payroll practices, but no less frequently than monthly. The base salary shall be reviewed at least annually by the Board and the Board may, but shall not be required to, increase the base salary during the employment term. Annual and Signing Bonus Suddarth is eligible to receive an annual bonus, as established by the Board and based on established performance milestones being achieved. Notwithstanding the foregoing, the Company shall pay Suddarth the following bonuses on the achievement of the following milestones and subject to the Board’s determination that the Company has sufficient capital: (i) $35,000 upon the commercial availability of a sheet type human amnion product; and (ii) $35,000 upon the third commercially available product; and (iii) $35,000 upon the fourth commercially available product In connection with the execution of the Suddarth Agreement, the Company agreed to pay Suddarth a $35,000 signing bonus which shall be accrued and paid by the Company upon the Company having sufficient cash flow. Warrant In connection with the execution of the Suddarth Agreement, the Company agreed to issue Suddarth a warrant to purchase, on a cashless basis, up to 23,850,000 shares of common stock of the Company for $0.02 per share, the closing price of the Company’s common stock on the effective date, exercisable in accordance with the vesting schedule below until the 10th anniversary of the date of issuance (“Suddarth Warrant”): Immediately on the effective date, 50% of the Suddarth Warrant shall vest and the remaining 50% shall vest in 18 equal monthly installments beginning on March 31, 2017 or until Suddarth no longer remains employed by the Company, whichever is earlier. Notwithstanding the foregoing vesting schedule, the unvested portion of the Suddarth Warrant shall be accelerated upon the achievement of the milestones set forth below, to the satisfaction of the Board in its sole discretion and contingent upon Suddarth’s continued employment at the time of consummation: a) 25% for the commercial availability of a sheet type human amnion product; and b) 15% for the third commercially available product; and c) 10% for the fourth commercially available product. Leases Ethan NY On September 3, 2015, Ethan NY entered into a five-year lease agreement (“Ethan Lease”) for a store located in New York City, New York. The Ethan Lease commenced on October 1, 2015. Under the terms of the Ethan Lease, Ethan NY provided an $18,585 security deposit and a former employee of Ethan NY provided a personal guaranty for a portion of the amounts due under the Ethan Lease. During June 2016, Ethan NY exited from its leased premises. Under the terms of the Ethan Lease, minimum monthly lease payments of $9,500 per month were to commence in December 2015 through October 2020. Ethan NY has not made any of the required minimum monthly lease payments as required including approximately $66,500 and $104,785 for the seven months ended June 30, 2016 and the eleven months ended October 31, 2016, respectively. The total amount of minimum lease payments that Ethan NY is obligated to pay pursuant to this 5-year lease is $586,242 (excluding late fees and interest provided for under the Ethan Lease). The lease payments pursuant to the Ethan Lease were as follows: Year Ended Minimum October 31, Rent 2016 $ 104,785 2017 117,714 2018 121,245 2019 124,882 2020 117,616 2021 - Total $ 586,242 All of Ethan NY’s obligations under the Ethan Lease are recourse only to the assets at Ethan NY, except for certain obligations under the Ethan Lease that were guaranteed by a former employee. Under the terms of the Ethan Lease, the obligations of Ethan NY for future rents are to be mitigated based on the amount of any future rents that are received for the rental of the leased premises to other tenants during the initial term. During August 2016, Ethan NY received confirmation that the leased premises had been leased to another tenant. In connection with the termination of the Ethan Lease, Ethan NY has made several unsuccessful attempts to contact the landlord for the purpose of obtaining a settlement and release for any amounts that the landlord may claim are owing under the Ethan Lease, if any. Ethan NY is not aware of any claim pending or threatened in connection with the Ethan Lease. At October 31, 2016, Ethan NY has recorded in liabilities of discontinued operations the amount of rent obligations through June 30, 2016 and a reserve for estimated losses in connection with termination of the Ethan Lease of $76,000 and $25,905, respectively. In addition, in connection with the termination of the Ethan Lease, Ethan NY recorded in its loss from discontinued operations the loss of the $18,585 security deposit made in connection with the execution of the Ethan Lease that is non-returnable to Ethan NY upon the occurrence of certain defined events prescribed under the Ethan Lease and the impairment loss of $5,463 associated with the remaining net amounts of furniture & fixtures and leasehold improvements that were remaining on the books and are not recoverable in connection with the termination of the Ethan Lease and the closing of the store location. Anu In connection with the Company’s decision to relocate its existing placental tissue bank processing laboratory in Miami, Florida, on May 23, 2017, our wholly-owned subsidiary, Anu Life Sciences Inc. entered into a five-year lease agreement (“Lab Lease”) for an approximately 3,500 square foot laboratory and administrative office facility in Sunrise, Florida. The Lab Lease is effective July 1, 2017 and expires on June 30, 2022 and provided for the ability of Anu to beginning moving into the premises beginning June 20, 2017. Under the terms of the Lab Lease, Anu has the option to renew the Lab Lease for two additional 5-year periods. Anu is also required to provide a $37,275 security deposit of which $18,638 is to be returned to Anu after the 2 nd Year Ended Minimum October 31, Rent 2017 $ 23,007 2018 90,020 2019 94,022 2020 102,877 2021 105,455 Thereafter 71,470 Total $ 486,850 The minimum lease payments described above exclude applicable Florida sales tax and additional rents as may be required under the terms of the Lab Lease. In accordance with the terms of the lease for the Company’s existing laboratory facility, the Company provided its notice of termination and as of June 20, 2017, completed the relocation of the lab facilities to the Sunrise leased premises. Termination of Contract On February 23, 2016, the Distribution Agreement, dated August 11, 2015, between Amnio Technology, LLC (“Amnio Technology”) and the Company’s wholly-owned subsidiary, BD Source, was terminated by Amnio Technology. Pursuant to the Distribution Agreement, Amnio Technology had engaged BD Source pursuant to the Distribution Agreement in connection with the marketing, sales and distribution of certain of Amnio Technology’s products. Amnio Technology is engaged in the business of human tissue procurement, processing and distribution to customers and third party distributors. Amnio Technology terminated the Distribution Agreement due to BD Source’s non-payment of the outstanding balance of $4,815 under the Distribution Agreement. BD Source has since paid such balance and believes that all obligations owed to Amnio Technology have been satisfied. Convertible Equity Securities Conversion of Notes issued in connection with the SPA In connection with the SPA, at any time after the six (6) month anniversary of the closing date and until the Note is no longer outstanding, any outstanding principal portion of the Note shall be convertible, in whole or in part, into shares of common stock of the Company at the option of each Purchaser (subject to the conversion limitations set forth in the SPA). The conversion price in effect on any conversion date shall be equal to the lower of (i) $0.15, and (ii) 60% of the lowest daily volume weighed average price in the 20 trading days prior to the conversion Date. Under the terms of the SPA, Bothwell and Werber are not eligible to convert their portion of the Note until the Agent has been fully repaid. In connection with the SPA, the Company will determine the underlying value attributable to the fair value of the embedded derivatives liabilities associated with the Notes at the issuance date based on an independent valuation using a Monte Carlo Model (the Notes contain full ratchet reset provisions and variable market based conversion derivative features). The Company will record the amount of the derivative liabilities at the time of closing as a reduction of the remaining initial carrying amount of the Notes and the excess amount after reducing the initial carrying amount of the Note to $0, if any, as a charge to the income statement. The derivative liability will be marked-to-market each quarter with the change in fair value recorded in the income statement. As of April 30, 2017, the amounts owed under the SPA, including original issue discount and accrued interest was approximately $531,826. Series A Preferred Stock of Mint Organics As more fully described in Note 12, each share of the Series A Preferred Stock shall automatically convert into 1.5 shares of Class B Common Stock of Mint Organics upon the earlier of (a) the fifth anniversary of the date such share of Series A Preferred Stock was issued; or (b) Mint Organics’ receipt of the necessary licenses and permits required to operate business operations in the medical cannabis industry. In addition, commencing on the first anniversary of the issuance date, each holder of the Series A Preferred Stock shall have the right, but not the obligation, to convert some or all of such holder’s shares of Series A Preferred Stock (or Class B Common Stock equivalent) into unregistered shares, par value $0.001 per share, of common stock of BPSR, based on the Stated Value divided by the average trading price of BPSR common stock for the ten trading days prior the conversion date. Notwithstanding the foregoing, the number of shares of Class B Common Stock issuable upon the conversion of the outstanding Series A Preferred Stock shall be adjusted to ensure that the outstanding Class B Common Stock represents 45% of the outstanding capital stock of Mint Organics (based on conversion of 300 shares of the Series A Preferred Stock or prorate portion thereof).

Mint Organics

Mint Organics	12 Months Ended
	Oct. 31, 2016
Mint Organics
Mint Organics	NOTE 12 – MINT ORGANICS On February 14, 2017, the Company entered into a participation agreement with Mr. Peter Taddeo (“Taddeo”) and Mr. Wayne Rohrbaugh (“Rohrbaugh”), two non-affiliated accredited investors (collectively, the “Investors”) in connection with the Company’s endeavor to obtain a license to dispense medical cannabis in Florida. Pursuant to the agreement, Taddeo and Rohrbaugh each invested $150,000 in the Company and the Company immediately established Mint Organics, Inc., a 55%-owned subsidiary of the Company and Mint Organics Florida, Inc., a wholly owned subsidiary of Mint Organics Inc., each dedicated to pursue the objectives of the Agreement. In connection with the agreement, $150,000 of the proceeds received from the Investors was obligated to be used to fund the operations of Mint Organics, Inc. and/or Mint Organics Florida, Inc. and the remainder was to be used for working capital of the Company. Mint Organics authorized capital consists of (i) 1,000 shares of Class A Voting Common Stock, par value $0.001 per share (“Class A Common Stock”); (ii) 1,000 shares of Class B Non-Voting Common Stock, par value $0.001 per share (“Class B Common Stock”); and (iii) 1,000 shares of Preferred Stock, par value $0.001 per share. BPSR owns 550 shares of Class A Common Stock, representing 100% of the outstanding shares of Class A Common Stock. There are no shares of Class B Common Stock currently outstanding. Pursuant to the Certificate Of Designation with respect to a Series A Convertible Preferred Stock (“Series A Preferred Stock”) filed on February 28, 2017 and as amended on March 23, 2017, Mint Organics authorized 300 shares of Series A Preferred Stock, par value $0.001 per share and a stated value of $1,000 per share. The Series A Preferred Stock is non-voting and non-redeemable. The amount of each share of the Series A Preferred Stock shall automatically convert into 1.5 shares of Class B Common Stock of Mint Organics upon the earlier of (a) the fifth anniversary of the date such share of Series A Preferred Stock was issued; or (b) Mint Organics’ receipt of the necessary licenses and permits required to operate business operations in the medical cannabis industry. In addition, commencing on the first anniversary of the issuance date, each holder of the Series A Preferred Stock shall have the right, but not the obligation, to convert some or all of such holder’s shares of Series A Preferred Stock (or Class B Common Stock equivalent) into unregistered shares, par value $0.001 per share, of common stock of BPSR, based on the stated value divided by the average trading price of BPSR common stock for the ten trading days prior the conversion date. Notwithstanding the foregoing, the number of shares of Class B Common Stock issuable upon the conversion of the outstanding Series A Preferred Stock shall be adjusted to ensure that the outstanding Class B Common Stock represents 45% of the outstanding capital stock of Mint Organics (based on conversion of 300 shares of the Series A Preferred Stock or pro rata portion thereof). In connection with the agreement, Mint Organics issued to each of Taddeo and Rohrbaugh (i) 150 shares of Series A Preferred Stock and (ii) a warrant exercisable for up to 150,000 shares of BPSR’s common stock for $0.15 per share exercisable from the date of issuance until the third anniversary of the date of issuance (see Note 10). In addition, in connection with the agreement, Taddeo was appointed as the Chief Executive Officer and as a director of Mint Organics, Inc. and Mint Organics Florida, Inc. Rohrbaugh was appointed as the Chief Operating Officer and as a director of Mint Organics, Inc. and Mint Organics Florida, Inc. On March 8, 2017, Mint Organics issued warrants to purchase shares of Class A Common Stock, of Mint Organics, Inc., vesting on the date Mint Organics, through one of its subsidiaries, obtains a license from a state to dispense cannabis until the fifth anniversary thereof to the following executives of Mint Organics: Name: Warrants Exercise Price: Albert Mitrani 79 $ 0.001 Ian T. Bothwell 79 $ 0.001 Dr. Maria I. Mitrani 79 $ 0.001 TOTAL 237 The Company evaluated the fair value of warrants issued, considering the contingency for the vesting of the warrants, the term of the warrants and the restrictive components of the underlying stock. In addition, the Company considered the contingencies, risks and viability typically associated with start-up businesses and the current uncertainty involving the conflict of state and federal legislation of the marijuana industry. As a result of its review, the Company determined that the value attributable to the warrants granted were nominal. Taddeo Employment Agreement Mint Organics entered into the “Taddeo Agreement” effective May 1, 2017, with Peter Taddeo (“Taddeo”), pursuant to which Taddeo will serve as the Chief Executive Officer (“Mint CEO”) of Mint Organics. Pursuant to the Taddeo Agreement, Mint Organics agreed to appoint Taddeo as a member of the board of directors of Mint Organics (“Mint Board”) for the term of the Taddeo Agreement, subject to state and federal law and the bylaws of Mint Organics, as long as Taddeo beneficially owns at least 3% of the common stock of Mint Organics. Below is a summary of the material terms of the Taddeo Agreement: Term The employment term shall continue until the third anniversary thereof, unless terminated earlier pursuant to the terms of the Taddeo Agreement; provided that, on such third anniversary of the effective date and each annual anniversary thereafter, the Taddeo Employment Agreement shall be deemed to be automatically extended, upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term of the Taddeo Agreement at least 90 days’ prior to the applicable renewal date. Base Salary Mint Organics shall pay Taddeo an annual rate of base salary of $180,000 during the period prior to Mint Organics, through one of its subsidiaries, or by other means, obtains or acquires access for a license from a state to dispense cannabis which shall accrue commencing as of the Effective Date and shall be payable upon Mint Organics generating sufficient net revenue or obtaining sufficient third party financing; and thereafter payable in periodic installments in accordance with Mint Organics’ customary payroll practices, but no less frequently than monthly. Taddeo’s base salary shall automatically be adjusted to an annual rate of base salary of $250,000 once the license is obtained. Annual and Signing Bonus Taddeo is eligible to receive an annual bonus, as established by the Mint Board and based on established performance milestones being achieved. The target bonus is expected to be a minimum of one times the Base Salary, consistent with bonuses that are paid to other key executive management members of Mint Organics and subject to determination and approval by the Mint Board. In connection with the execution of the Taddeo Agreement, Mint Organics agreed to pay Taddeo a $25,000 signing bonus which shall be accrued and paid by Mint Organics upon Mint Organics having sufficient cash flow. Equity Awards As incentive to enter into the Taddeo Agreement, on the Effective Date, the Company granted Taddeo 1,000,000 shares of unregistered Common Stock of BPSR, vesting on the date Mint Organics, through one of its subsidiaries, obtains a license from a state to dispense cannabis or December 31, 2017, whichever is earlier, and provided that Taddeo’s employment has not been terminated prior to the time the vesting conditions have been met. Mint Organics Florida, Inc. Mint Organics Florida, Inc.’s authorize capital structure consists of (1) 10,000 shares of Class A Voting Common Stock, par value $0.001 per share and (ii) 10,000 shares of Class B Non-Voting Common Stock, par value $0.001 per share. The Class A Common Stock shall have the sole right and power to vote on all matters on which a vote of shareholders is to be taken. In all matters, with respect to actions both by vote and by consent, each holder of shares of the Class A Common Stock shall be entitled to cast one vote in person or by proxy for each share of Class A Common Stock standing in such holder’s name on the transfer books of the Corporation. The Class B Common Stock shall not be entitled to vote on any matters. On February 28, 2017, the Board of Mint Organics Florida, Inc. issued 2,125 shares of Class A Voting Common Stock, par value $0.001 per share, of Mint Organics Florida, Inc. to Mint Organics, Inc. and determined that the fair consideration for the initial issuance of the Series A Voting Common Stock is $0.001 per share. Offering: On March 17, 2017, Mint Organics Florida initiated an offering to raise up to $1,000,000 in exchange for up to 212.5 shares of Class B common stock, representing approximately 10.0% of the outstanding equity of Mint Organics Florida as of the date of the offering. The proceeds of the offering are to be used for general working capital purposes. On April 6, 2017, Mint Organics received proceeds of $100,000 in connection with the sale of 21.25 units to an investor in connection with the offering. Agreements: On February 15, 2017, Mint Organics Florida entered into a consulting agreement with a lobbying firm in connection with Mint Organics Florida’s efforts to obtain a license to dispense medical cannabis in Florida. The initial term of the agreement is for a minimum period of one year and will automatically renew for additional one-year terms unless either party provides 60 days’ prior written notice of intent to cancel the agreement. Under the terms of the agreement, Mint Organics Florida is required to pay a monthly fee of $7,500, plus expenses and upon Mint Organics Florida’s receipt of a license to dispense medical cannabis in Florida, the Consulting Firm will be entitled to receive a 3% equity interest in Mint Organics Florida through granting of 63.75 shares of Class B Common Stock of Mint Organics Florida.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Oct. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	NOTE 13 – DISCONTINUED OPERATIONS On October 30, 2015, the Company entered into a stock purchase agreement with John Goodhew, the Company’s director, pursuant to which all of the shares of Bespoke Tricycles, Ltd., a corporation organized under the Laws of England and Wales, were transferred to Mr. Goodhew. As a result of such sale, the Company is no longer in the business of designing, manufacturing, and selling vending tricycles. The purchase price for the shares sold to Mr. Goodhew was $10. Mr. Goodhew resigned as a member of the Board of Directors in connection with the execution and delivery of the stock purchase agreement on October 30, 2015. During September 2015, the Company formed Ethan NY for the purpose of selling clothing and accessories through a retail store. During June 2016, the Ethan NY operations were closed and as a result the operations of Ethan NY have been reflected as discontinued operations in the financial statements. The following summarizes the carrying amounts of the assets and liabilities of Ethan NY at October 31, 2016 and 2015. There were no carrying amounts of the assets and liabilities of Bespoke as of October 31, 2016 and 2015: October 31, 2016 2015 Assets: Cash $ - $ 61,730 Inventories - 1,608 Prepaid Expenses - 1,250 Security Deposits - 18,585 Property, Plant and Equipment, net - 6,180 $ - $ 89,353 Liabilities: Accounts Payable $ 94,835 $ - Accrued Expenses 31,016 - Deferred Rent - 9,771 $ 125,851 $ 9,771 The loss on disposal of Bespoke is summarized below: Year Ended October 31, 2016 October 31, 2015 Cash received $ - $ 10 Total consideration - 10 Bespoke’s net assets - (5,679 ) Loss on disposal of Bespoke $ - $ (5,669 ) The following summaries Bespoke’s and Ethan NY’s revenues and expenses, net and net income of discontinued operations: Year Ended October 31, 2016 2015 Revenues: Bespoke $ - $ 54,008 Ethan NY 68,598 - Total Revenues 68,598 54,008 Expenses, net: Bespoke - 23,812 Ethan NY 265,753 18,572 Total Expenses, net 265,753 42,384 Loss on disposal of Bespoke: - (5,669 ) Income (Loss) From Discontinued Operations: Bespoke - 24,527 Ethan NY (197,155 ) (18,572 ) Income (Loss) From Discontinued Operations $ (197,155 ) $ 5,955

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Oct. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform with the current financial statement presentation including adjusted footnotes to reflect the presentation of discontinued operations as further discussed in Note 13.
Concentrations of Credit Risk	Concentrations of Credit Risk The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $250,000 per institution. At October 31, 2016, we did not have any cash balances in financial institutions in excess of FDIC insurance coverage. During the fiscal year ended October 31, 2016, one customer accounted for approximately $27,000 or 14.5% of revenues. During the fiscal year ended October 31, 2016, we purchased products from one supplier totaling approximately $53,000 or 56.0% of our cost of revenues. The Company’s sales and supply agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products and/or the availability of products from other suppliers. Since February 2017, the Company commenced the manufacturing and distribution of proprietary products that will further reduce exposure by increasing its ability to sell to customers and eliminate reliance on third party suppliers.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. For the year ended October 31, 2016 and 2015, the Company recorded bad debt expense of $500 and $0.
Inventory	Inventory Inventory is stated at the lower of cost or market using the average cost method. The Company regularly reviews inventory quantities on hand to identify slow-moving merchandise and markdowns necessary to clear slow-moving merchandise. Estimates of markdown requirements may differ from actual results due to changes in quantity, quality and mix of products in inventory, as well as changes in consumer preferences, market and economic conditions.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of property and equipment range from 3 to 5 years. Upon sale or retirement, the cost and related accumulated depreciation and amortization are eliminated from their respective accounts, and the resulting gain or loss is included in results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred.
Revenue Recognition	Revenue Recognition The Company recognizes revenue on arrangements in accordance with FASB ASC Topic. 605 “Revenue Recognition”. In all cases, revenue is recognized only when the price is fixed and determinable, persuasive evidence of an arrangement exists, the service is performed and collectability of the resulting receivable is reasonably assured.
Net Income (Loss) Per Common Share	Net Income (Loss) Per Common Share Basic income (loss) per common share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. At October 31, 2016, the Company had 1,737,479 common shares issuable upon the exercise of warrants that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the year ended October 31, 2016. At October 31, 2015, the Company had 1,008,114 common shares issuable upon the exercise of warrants that were not included in the computation of dilutive loss per share because their inclusion is anti-dilutive for the year ended October 31, 2015.
Stock-Based Compensation	Stock-Based Compensation All stock-based payments to employees, including grants of employee stock options, are recognized in the financial statements based on their fair values. Stock options and warrants issued to consultants and other non-employees as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can be more clearly determined.
Foreign Currency Translation	Foreign Currency Translation The functional currency of Bespoke was British pounds and was translated to U.S. dollars using the exchange rate effective for the date reported for assets and liabilities and the average exchange rate for the period reported for revenues and expenses.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company follows FASB ASC 820, Fair Value Measurement, which clarifies fair value as an exit price, establishes a hierarchal disclosure framework for measuring fair value, and requires extended disclosures about fair value measurements. The provisions of ASC 820 apply to all financial assets and liabilities measured at fair value. As defined in ASC 820, fair value, clarified as an exit price, represents the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a result, fair value is a market-based approach that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering these assumptions, ASC 820 defines a three-tier value hierarchy that prioritizes the inputs used in the valuation methodologies in measuring fair value. Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
Subsequent Events	Subsequent Events The Company has evaluated subsequent events that occurred after October 31, 2016 through the financial statement issuance date for subsequent event disclosure consideration.
New Accounting Pronouncements	New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014- 09, “Revenue from Contracts with Customers (Topic 606).” The new guidance provides new criteria for recognizing revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new guidance requires expanded disclosures to provide greater insight into both revenue that has been recognized and revenue that is expected to be recognized in the future from existing contracts. Quantitative and qualitative information will be provided about the significant judgments and changes in those judgments that management made to determine the revenue that is recorded. This accounting standard update, as amended, will be effective for annual reporting periods beginning after December 15, 2018, and interim reporting periods within annual reporting periods beginning after December 15, 2019. The new revenue standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. Early adoption is permitted, but no earlier than fiscal 2017. The Company is currently assessing the provisions of the guidance and has not determined the impact of the adoption of this guidance on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The new standard requires management to assess the company’s ability to continue as a going concern. Disclosures are required if there is substantial doubt as to the company’s continuation as a going concern within one year after the issue date of financial statements. The standard provides guidance for making the assessment, including consideration of management’s plans which may alleviate doubt regarding the Company’s ability to continue as a going concern. ASU 2014-15 is effective for years ending after December 15, 2016. Early adoption is permitted. The Company has adopted this standard for the year ending October 31, 2016, and management has concluded that there is substantial doubt as to the Company’s continuation as a going concern within one year after the issue date of the financial statements. In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is currently evaluating the impact of the new pronouncement on its financial statements. In April 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation” (topic 718). The FASB issued this update to improve the accounting for employee share-based payments and affect all organizations that issue sharebased payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The updated guidance is effective for annual periods beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption of the update is permitted. The Company adopted this guidance in the first quarter of 2017. The adoption of this update had no material effect on the Company’s financial position or results of operations. The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Oct. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Inventories	ANU inventory was associated with materials acquired for the manufacturing of products to be sold in 2017. October 31, 2016 October 31, 2015 ANU materials $ 9,944 $ - Total Inventories $ 9,944 $ -

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Oct. 31, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	October 31, 2016 October 31, 2015 Computer equipment $ 1,724 $ 1,724 Manufacturing equipment 26,313 - 28,037 1,724 Less: accumulated depreciation and amortization (431 ) (86 ) Total property and equipment, net $ 27,606 $ 1,638

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Oct. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the U.S. federal statutory tax amount to the Company’s effective tax amount is as follows: Year Ended October 31, 2016 Year Ended October 31, 2015 Income tax benefit at statutory rate (34%) $ (426,088 ) $ (251,040 ) Stock-based compensation - 91,120 Valuation allowance 426,088 159,920 Total $ - $ -
Schedule of Deferred Tax Assets and Liabilities	The tax effects of temporary differences and carry-forwards that give rise to deferred tax assets and liabilities for the Company were as follows: October 31, 2016 October 31, 2015 Deferred tax asset attributable to: Net operating loss carry-forward $ 627,507 $ 201,419 Less valuation allowance (627,507 ) (201,419 ) Total $ - $ -

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Oct. 31, 2016
Warrants
Schedule of Warrants Granted to Purchase Shares of Common Stock	On March 8, 2017, the Board of the Company granted warrants to purchase shares of common stock of the Company on a cashless basis to the following executive officers and directors of the Company: Executive Officer Warrants: Dr. Bruce Werber (Chief Operating Officer and Director) 21,500,000 Ian T. Bothwell (Chief Financial Officer and Director) 21,500,000 Dr. Maria Ines Mitrani (Chief Science Officer and Director) 13,850,000 TOTAL 56,850,000
Summary of Warrant Activity	A summary of warrant activity for the years ended October 31, 2015 and 2016 are presented below. Number of Shares Weighted-average Exercise Price Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at October 31, 2014 - $ - Granted 1,008,114 $ 0.75 4.00 $ - Exercised - $ - Expired/Forfeited - $ - Outstanding and exercisable at October 31, 2015 1,008,114 $ 0.75 3.78 $ - Number of Shares Weighted-average Exercise Price Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at October 31, 2015 1,008,114 $ 0.75 3.78 $ - Granted 729,370 $ 0.75 4.00 $ - Exercised - $ - Expired/Forfeited - $ - Outstanding and exercisable at October 31, 2016 1,737,484 $ 0.75 3.01 $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Oct. 31, 2016
Schedule of Lease Payments	The lease payments pursuant to the Ethan Lease were as follows: Year Ended Minimum October 31, Rent 2016 $ 104,785 2017 117,714 2018 121,245 2019 124,882 2020 117,616 2021 - Total $ 586,242
Anu Life Sciences Inc [Member]
Schedule of Lease Payments	The minimum lease payments pursuant to Lab Lease are as follows: Year Ended Minimum October 31, Rent 2017 $ 23,007 2018 90,020 2019 94,022 2020 102,877 2021 105,455 Thereafter 71,470 Total $ 486,850

Mint Organics (Tables)

Mint Organics (Tables)	12 Months Ended
	Oct. 31, 2016
Mint Organics
Schedule of Warrants Issued to Purchase Common Stock for Executives	On March 8, 2017, Mint Organics issued warrants to purchase shares of Class A Common Stock, of Mint Organics, Inc., vesting on the date Mint Organics, through one of its subsidiaries, obtains a license from a state to dispense cannabis until the fifth anniversary thereof to the following executives of Mint Organics: Name: Warrants Exercise Price: Albert Mitrani 79 $ 0.001 Ian T. Bothwell 79 $ 0.001 Dr. Maria I. Mitrani 79 $ 0.001 TOTAL 237

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Oct. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet and Additional Disclosures	The following summarizes the carrying amounts of the assets and liabilities of Ethan NY at October 31, 2016 and 2015. There were no carrying amounts of the assets and liabilities of Bespoke as of October 31, 2016 and 2015: October 31, 2016 2015 Assets: Cash $ - $ 61,730 Inventories - 1,608 Prepaid Expenses - 1,250 Security Deposits - 18,585 Property, Plant and Equipment, net - 6,180 $ - $ 89,353 Liabilities: Accounts Payable $ 94,835 $ - Accrued Expenses 31,016 - Deferred Rent - 9,771 $ 125,851 $ 9,771 The loss on disposal of Bespoke is summarized below: Year Ended October 31, 2016 October 31, 2015 Cash received $ - $ 10 Total consideration - 10 Bespoke’s net assets - (5,679 ) Loss on disposal of Bespoke $ - $ (5,669 ) The following summaries Bespoke’s and Ethan NY’s revenues and expenses, net and net income of discontinued operations: Year Ended October 31, 2016 2015 Revenues: Bespoke $ - $ 54,008 Ethan NY 68,598 - Total Revenues 68,598 54,008 Expenses, net: Bespoke - 23,812 Ethan NY 265,753 18,572 Total Expenses, net 265,753 42,384 Loss on disposal of Bespoke: - (5,669 ) Income (Loss) From Discontinued Operations: Bespoke - 24,527 Ethan NY (197,155 ) (18,572 ) Income (Loss) From Discontinued Operations $ (197,155 ) $ 5,955

Organization and Description 29

Organization and Description of Business (Details Narrative) - $ / shares	May 29, 2015	Oct. 31, 2016	Oct. 30, 2015
Mint Organics, Inc [Member] | February 2017 [Member]
Percentage of owned subsidiary		55.00%
John Goodhew [Member]
Number of common stock shares purchased during the period	135,000,000
John Goodhew [Member] | Stock Purchase Agreement [Member]
Purchase price per share			$ 10

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2016	Oct. 31, 2015
FDIC limits per institutions	$ 250,000
Revenue	184,881	$ 147,629
Cost of revenues	94,402	49,411
Bad debt expense	$ 500
Common Shares Issuable Upon Exercise of Warrants [Member]
Antidilutive securities excluded from computation of earnings per share	1,737,479	1,008,114
Minimum [Member]
Property and equipment estimated useful lives	3 years
Maximum [Member]
Property and equipment estimated useful lives	5 years
One Customer [Member]
Revenue	$ 27,000
Concentration credit risk percentage	14.50%
One Supplier [Member]
Concentration credit risk percentage	56.00%
Cost of revenues	$ 53,000

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2016	Oct. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 1,253,201	$ 738,354
Accumulated deficit	2,113,611	$ 860,410
Working capital deficit	$ 851,680

Inventories (Details Narrative)

Inventories (Details Narrative) - USD ($)	Oct. 31, 2016	Oct. 31, 2015
Inventory Disclosure [Abstract]
Inventories	$ 9,944

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($)	Oct. 31, 2016	Oct. 31, 2015
Inventory Disclosure [Abstract]
ANU materials	$ 9,944
Total Inventories	$ 9,944

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2016	Oct. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 345	$ 86

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Oct. 31, 2016	Oct. 31, 2015
Property and equipment, gross	$ 28,037	$ 1,724
Less: accumulated depreciation and amortization	(431)	(86)
Total property and equipment, net	27,606	1,638
Computer Equipment [Member]
Property and equipment, gross	1,724	1,724
Manufacturing Equipment [Member]
Property and equipment, gross	$ 26,313

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	May 28, 2015	Feb. 19, 2015	Oct. 31, 2016	Oct. 31, 2015
Reimbursement to former director				$ 4,604
Forgiveness of related party loan				42,058
Lease term			24 months
Monthly rent expense			$ 2,500
Security deposit			$ 5,000
Preferred stock, shares issued			0	0
Preferred stock par value			$ 0.001	$ 0.001
Warrant to purchase shares of common stock			729,370	1,008,114
Number of sold shares of common stock	1,800,000	1,800,000
Cost of sale related parties			$ 15,703
March 8, 2017 [Member]
Warrant exercise price per share			$ 0.02
March 8, 2017 [Member] | Series A Preferred Stock [Member]
Preferred stock voting percentage			The Series A Preferred Stock shall vote together with the shares of common stock and other voting securities of the Company as a single class and such shares shall represent 80% of all votes entitled to be voted at any annual or special meeting of stockholders of the Company or action by written consent of stockholders.
May 17, 2017 [Member] | Executive Employment Agreement [Member] | Peter Taddeo [Member]
Number of unregistered restricted common stock shares			1,000,000
Unregistered restricted Common Stock valued per share			$ 0.012
Maximum [Member]
Monthly rent expense			$ 2,500
Chief Executive Officer [Member]
Salary expense			241,845	$ 118,846
Paid salary			91,845	88,039
Salary and consulting fees			138,729	78,773
Paid salary and consulting fees			33,896	69,419
Health benefit costs and automobile related allowances			46,868	$ 11,281
Reimbursed expenses			44,000
Accrued salary related expense			150,000
Due to related party			$ 150,000
Chief Executive Officer [Member] | November 1, 2016 [Member] | Series A Preferred Stock [Member]
Preferred stock, shares issued			100
Preferred stock par value			$ 0.001
Chief Executive Officer [Member] | March 8, 2017 [Member]
Warrant to purchase shares of common stock			79
Warrant exercise price per share			$ 0.001
Chief Science Officer [Member]
Accrued salary related expense			$ 104,833
Due to related party			$ 104,833
Chief Science Officer [Member] | March 8, 2017 [Member]
Warrant to purchase shares of common stock			79
Warrant exercise price per share			$ 0.001
Chief Science Officer [Member] | March 8, 2017 [Member] | Series A Preferred Stock [Member]
Preferred stock, shares issued			100
Chief Financial Officer [Member]
Due to officer			$ 70,000
Chief Financial Officer [Member] | March 29, 2017 [Member]
Due to officer			150,000
Converted amount of advances and unreimbursed expenses			$ 300,000
Number of common shares granted			1,000,000
Number of common shares granted, value			$ 31,790
Chief Financial Officer [Member] | March 8, 2017 [Member]
Warrant to purchase shares of common stock			79
Warrant exercise price per share			$ 0.001
Chief Financial Officer [Member] | March 8, 2017 [Member] | Series A Preferred Stock [Member]
Preferred stock, shares issued			100
Chief Operating Officer [Member]
Due to officer			$ 53,000
Chief Operating Officer [Member] | March 29, 2017 [Member]
Due to officer			150,000
Converted amount of advances and unreimbursed expenses			$ 300,000
Number of common shares granted			1,000,000
Number of common shares granted, value			$ 31,790
Chief Operating Officer [Member] | March 8, 2017 [Member] | Series A Preferred Stock [Member]
Preferred stock, shares issued			100
Chief Operating Officer [Member] | February 2017 [Member]
Number of sold shares of common stock			250,000
Sale of stock price per share			$ 0.04
Aggregate purchase price			$ 10,000
Mr. Peter Taddeo [Member] | February 14, 2017 [Member]
Preferred stock, shares issued			150
Warrant to purchase shares of common stock			150,000
Warrant exercise price per share			$ 0.15
Invested amount			$ 150,000
Mr. Wayne Rohrbaugh [Member] | February 14, 2017 [Member]
Preferred stock, shares issued			150
Warrant to purchase shares of common stock			150,000
Warrant exercise price per share			$ 0.15
Invested amount			$ 150,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative)	Apr. 27, 2016USD ($)	Dec. 24, 2015USD ($)	Nov. 12, 2015USD ($)	Oct. 31, 2017USD ($)	Oct. 31, 2016USD ($)Days$ / sharesshares	Oct. 31, 2015USD ($)
Number of common shares issued, value					$ 457,279	$ 496,200
Initial Tranche [Member]
Payment of note payable				$ 15,000
Second Tranche [Member]
Payment of note payable				50,000
Third Tranche [Member]
Payment of note payable				$ 35,000
Unsecured Loan Agreement [Member]
Debt principal amount	$ 35,000	$ 50,000	$ 15,000
Proceeds from issuance of debt	35,000	50,000	15,000
Note payable	$ 42,000	$ 50,000	$ 15,000
Debt interest percentage	221.00%	8.00%	8.00%
Debt term		1 year	1 year
Debt due date	May 31, 2016
Securities Purchase Agreement [Member]
Debt principal amount					333,333
Debt subscription amount					300,000
Remaining amount of debt					$ 175,000
Participate tranche description					In the event that any Purchaser does not participate in any Tranche after the second Tranche, the remaining Purchasers shall have the right to participate in such Tranche in an amount up to 100% of the entire Tranche. In the event that such participating Purchasers do not collectively fund 100% of the desired Tranche amount, then the Company shall be permitted to request from any Person (as defined in the SPA) the remaining amount, so long as such Person(s) agree to execute the SPA (and further, the Company and the Purchasers agree to amend the Agreement and the Note as necessary). The Company is not obligated to consummate any additional Tranche fundings subsequent to the second Tranche.
Initial carrying amount of note					$ 0
Securities Purchase Agreement [Member] | Ian T. Bothwell [Member]
Number of common shares issued | shares					1,000,000
Number of common shares issued, value					$ 63,580
Securities Purchase Agreement [Member] | Agent [Member]
Number of common shares issued | shares					2,000,000
Number of common shares issued, value					$ 63,580
Securities Purchase Agreement [Member] | Werber [Member]
Number of common shares issued | shares					1,000,000
Number of common shares issued, value					$ 63,580
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member]
Debt principal amount					$ 1,666,667
Debt interest percentage					10.00%
Debt due date					Mar. 31, 2018
Percentage of original issue of discount					10.00%
Debt subscription amount					$ 1,500,000
Debt description					The unpaid principal amount of the Note shall accrue interest at 10% per annum, provided that upon the occurrence and during the continuance of an event of default as defined in the SPA, the outstanding principal amount of this Note and any accrued and unpaid interest and all other overdue amounts shall each bear interest until paid at the rate of 18% per annum. Additionally, in the event that the publicly traded price of the common stock falls below $0.0125 for 3 consecutive trading days, then the Note shall accrue interest at the default interest rate. During the period April 27, 2017 to May 1, 2017, the closing price of the common stock fell below $0.0125 and accordingly beginning May 2, 2017, the default interest rate of 18% is in effect.
Debt default interest rate					18.00%
Debt stock price per share | $ / shares					$ 0.0125
Debt trading days | Days					3
Debt conversion price per share | $ / shares					$ 0.15
Debt conversion price percentage					60.00%
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member] | Minimum [Member]
Prepayment penalty percentage					20.00%
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member] | Maximum [Member]
Prepayment penalty percentage					40.00%
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member] | Initial Tranche [Member]
Debt principal amount					$ 527,778
Debt subscription amount					475,000
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member] | Second Tranche [Member]
Debt principal amount					138,889
Debt subscription amount					125,000
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member] | Purchasers [Member]
Debt principal amount					666,667
Debt subscription amount					600,000
Securities Purchase Agreement [Member] | April 3, 2017 [Member]
Payment of note payable					$ 15,000
Securities Purchase Agreement [Member] | April 27, 2017 to May 1, 2017 [Member]
Debt default interest rate					18.00%
Debt stock price per share | $ / shares					$ 0.0125
Securities Purchase Agreement One [Member] | April 3, 2017 [Member]
Payment of note payable					$ 50,000
Securities Purchase Agreement Two [Member] | April 3, 2017 [Member]
Payment of note payable					$ 35,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Oct. 31, 2016USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 1,845,000
Operating loss expiration	will expire beginning in 2031
Valuation of allowance percentage	100.00%

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Reconciliation of Income Tax (Details) - USD ($)	12 Months Ended
	Oct. 31, 2016	Oct. 31, 2015
Income Tax Disclosure [Abstract]
Income tax benefit at statutory rate (34%)	$ (426,088)	$ (251,040)
Stock-based compensation		91,120
Valuation allowance	426,088	159,920
Total

Income Taxes - Schedule of Ef40

Income Taxes - Schedule of Effective Reconciliation of Income Tax (Details) (Parenthetical)	12 Months Ended
	Oct. 31, 2016	Oct. 31, 2015
Income Tax Disclosure [Abstract]
Percentage of statutory income tax rate	34.00%	34.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Oct. 31, 2016	Oct. 31, 2015
Income Tax Disclosure [Abstract]
Net operating loss carry-forward	$ 627,507	$ 201,419
Less valuation allowance	(627,507)	(201,419)
Total

Capital Stock (Details Narrativ

Capital Stock (Details Narrative) - USD ($)	Sep. 17, 2015	Jul. 09, 2015	May 28, 2015	Feb. 19, 2015	Sep. 30, 2016	Aug. 31, 2016	Jul. 31, 2016	Apr. 30, 2016	Sep. 30, 2015	Oct. 31, 2015	Sep. 02, 2015	Mar. 31, 2016	Oct. 31, 2016	Oct. 30, 2016	Oct. 31, 2015	Oct. 31, 2017
Preferred stock, shares authorized										10,000,000			10,000,000		10,000,000
Preferred stock, par value										$ 0.001			$ 0.001		$ 0.001
Preferred stock, shares issued										0			0		0
Common stock, shares authorized										750,000,000			750,000,000		750,000,000
Common stock, par value										$ 0.001			$ 0.001		$ 0.001
Forward stock split	eighteen-for-one forward stock split
Number of common stock shares sold during the period			1,800,000	1,800,000
Proceeds from issuance of common stock			$ 25,000	$ 25,000									$ 457,279		$ 496,200
Warrants to purchase share of common stock										1,008,114			729,370		1,008,114
Fair value of warrants issued													$ 379,893		$ 174,323
Stock-based compensation expense									$ 268,000
Forgiveness of related party loan															42,058
Common Stock [Member]
Forgiveness of related party loan
Chief Executive Officer [Member]
Number of common stock shares cancelled during the period		60,120,000
Third Parties [Member]
Number of common stock shares sold during the period											311,200
Sale of stock, price per share											$ 1
Warrant term											4 years
Fair value of warrants issued											$ 91,263
Third Parties [Member] | One Class A Warrant [Member]
Warrants to purchase share of common stock											311,200
Exercise price of warrants											$ 0.50
Third Parties [Member] | One Class B Warrant [Member]
Warrants to purchase share of common stock											311,200
Exercise price of warrants											$ 1
Third Parties [Member] | Common Stock [Member]
Number of common stock shares sold during the period											622,400
Investors [Member]
Number of common stock shares sold during the period							2,200,000			192,857
Proceeds from issuance of common stock							$ 92,000
Sale of stock, price per share										$ 0.70					$ 0.70
Warrant term										4 years
Fair value of warrants issued										$ 83,060
Offering costs							$ 18,000
Investors [Member] | One Class A Warrant [Member]
Warrants to purchase share of common stock										192,857					192,857
Exercise price of warrants										$ 0.50					$ 0.50
Investors [Member] | One Class B Warrant [Member]
Warrants to purchase share of common stock										192,857					192,857
Exercise price of warrants										$ 1					$ 1
Investors [Member] | Common Stock [Member]
Number of common stock shares sold during the period										385,714
Consultant [Member]
Number of common stock shares sold during the period									4,590,000
Director [Member]
Forgiveness of related party loan															$ 42,058
9 Accredited Investors [Member]
Number of common stock shares sold during the period												364,685
Proceeds from issuance of common stock												$ 255,279
Sale of stock, price per share												$ 0.70
9 Accredited Investors [Member] | One Class A Warrant [Member]
Warrants to purchase share of common stock												364,685
Exercise price of warrants												$ 0.50
9 Accredited Investors [Member] | One Class B Warrant [Member]
Warrants to purchase share of common stock												364,685
Exercise price of warrants												$ 1
9 Accredited Investors [Member] | Common Stock [Member]
Number of common stock shares sold during the period												729,370
Warrant term												4 years
Fair value of warrants issued												$ 379,893
Individual [Member]
Number of common stock shares sold during the period								25,000
Proceeds from issuance of common stock								$ 5,000
Accredited Investors [Member]
Number of common stock shares sold during the period					2,000,000	62,500
Proceeds from issuance of common stock					$ 100,000	$ 5,000
Sale of stock, price per share					$ 0.05	$ 0.08
Maximum [Member]
Common stock, shares authorized													250,000,000
Common stock, par value													$ 0.001
Series A Non-Convertible Preferred Stock [Member]
Preferred stock voting rights													The outstanding shares of Series A Non-Convertible Preferred Stock shall vote together with the shares of Common Stock and other voting securities of the Company as a single class and, regardless of the number of shares of Series A Non-Convertible Preferred Stock outstanding, and as long as at least one share of Series A Non-Convertible Preferred Stock is outstanding, such shares shall represent eighty percent (80%) of all votes entitled to be voted at any annual or special meeting of stockholders of the Company or action by written consent of stockholders. Each outstanding share of the Series A Non-Convertible Preferred Stock shall represent its proportionate share of the 80% which is allocated to the outstanding shares of Series A Non-Convertible Preferred Stock.
November 1, 2016 [Member] | Series A Non-Convertible Preferred Stock [Member]
Preferred stock, shares authorized													10,000,000
Preferred stock, par value													$ 0.001
Preferred stock, shares issued													100
November 1, 2016 [Member] | Series A Non-Convertible Preferred Stock [Member] | Chief Executive Officer [Member]
Preferred stock, par value													$ 0.001
Preferred stock, shares issued													100
November 1, 2016 [Member] | Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized													10,000,000
Preferred stock, shares designated													1,000,000
March 2, 2017 [Member] | Series A Non-Convertible Preferred Stock [Member] | Minimum [Member]
Preferred stock, shares designated													100
March 2, 2017 [Member] | Series A Non-Convertible Preferred Stock [Member] | Maximum [Member]
Preferred stock, shares designated													400
March 8, 2017 [Member] | Parent Company [Member] | Mint Organics, Inc [Member] | Consulting Services [Member]
Sale of stock, price per share													$ 0.02
Stock-based compensation expense													$ 2,000
Issuance of shares of unregistered common stock													100,000
March 8, 2017 [Member] | Series A Non-Convertible Preferred Stock [Member] | COO [Member]
Preferred stock, shares issued													100
March 8, 2017 [Member] | Series A Non-Convertible Preferred Stock [Member] | CSO [Member]
Preferred stock, shares issued													100
March 8, 2017 [Member] | Series A Non-Convertible Preferred Stock [Member] | CFO [Member]
Preferred stock, shares issued													100
June 6, 2017 [Member] | Minimum [Member]
Common stock, shares authorized													250,000,000
June 6, 2017 [Member] | Maximum [Member]
Common stock, shares authorized													750,000,000
June 6, 2017 [Member] | Series A Preferred Stock [Member]
Percentage of voting equivalency of outstanding capital stock																80.00%
January 2017 [Member] | Accredited Investors [Member]
Number of common stock shares sold during the period														100,000
Proceeds from issuance of common stock														$ 5,000
Sale of stock, price per share													$ 0.05
January 2017 to February 2017 [Member]
Number of common stock shares sold during the period													90,000
Proceeds from issuance of common stock													$ 90,000
Sale of stock, price per share													$ 0.10
Warrant term													3 years
Fair value of warrants issued													$ 33,480
January 2017 to February 2017 [Member] | One Class A Warrant [Member]
Warrants to purchase share of common stock													900,000
Exercise price of warrants													$ 0.075
January 2017 to February 2017 [Member] | One Class B Warrant [Member]
Warrants to purchase share of common stock													900,000
Exercise price of warrants													$ 0.150
January 2017 to February 2017 [Member] | Common Stock [Member]
Number of common stock shares sold during the period													1,800,000
February 2017 [Member] | Related Party [Member]
Number of common stock shares sold during the period													250,000
Proceeds from issuance of common stock													$ 10,000
Sale of stock, price per share													$ 0.04
March 29, 2017 [Member] | Agent [Member] | Securities Purchase Agreement [Member]
Number of common stock shares sold during the period													2,000,000
Proceeds from issuance of common stock													$ 63,580
March 29, 2017 [Member] | Werber [Member] | Securities Purchase Agreement [Member]
Number of common stock shares sold during the period													1,000,000
Proceeds from issuance of common stock													$ 63,580
March 29, 2017 [Member] | Bothwell [Member] | Securities Purchase Agreement [Member]
Number of common stock shares sold during the period													1,000,000
Proceeds from issuance of common stock													$ 63,580
March17, 2017 [Member] | Taddeo [Member] | Taddeo Agreement [Member]
Number of common stock shares sold during the period													1,000,000
Proceeds from issuance of common stock													$ 12,000
Sale of stock, price per share													$ 0.012

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	Nov. 04, 2016	Oct. 31, 2016	Oct. 31, 2015
Number of warrant shares issued		729,370	1,008,114
Expected term		4 years	4 years
Expected volatility			100.00%
Expected dividend rate		0.00%	0.00%
Fair value of warrants		$ 379,893	$ 174,323
Proceeds from debt financing			$ 300
Human Amnion Product [Member]
Commercially available product percentage		25.00%
Third Product [Member]
Commercially available product percentage		15.00%
Fourth Product [Member]
Commercially available product percentage		10.00%
During January 2017 and February 2017 [Member]
Number of warrant shares issued		1,800,000
Expected term		3 years
Expected volatility		106.00%
Expected dividend rate		0.00%
Fair value of warrants		$ 33,480
March 8, 2017 [Member]
Risk free interest rate		2.57%
Expected term		10 years
Expected volatility		153.00%
Expected dividend rate		0.00%
Fair value of warrants		$ 1,119,945
Exercise price of warrants		$ 0.02
Participation Agreement [Member] | March 8, 2017 [Member]
Number of warrant shares issued		150,000
Risk free interest rate		1.38%
Expected term		3 years
Expected volatility		106.00%
Expected dividend rate		0.00%
Fair value of warrants		$ 4,770
Exercise price of warrants		$ 0.15
Employment Agreement [Member] | March 8, 2017 [Member]
Number of warrant shares issued		23,850,000
Risk free interest rate		2.57%
Expected term		10 years
Expected volatility		153.00%
Expected dividend rate		0.00%
Fair value of warrants		$ 469,845
Exercise price of warrants		$ 0.02
Warrant vesting description		Immediately on the Effective Date, 50% of the Warrant shall vest and, thereafter, the remaining 50% shall vest in 18 equal monthly installments beginning on March 31, 2017
Ian T. Bothwell [Member]
Number of warrant shares issued		31,800,000
Risk free interest rate		1.79%
Expected term		10 years
Expected volatility		152.00%
Expected dividend rate		0.00%
Fair value of warrants		$ 1,879,380
Exercise price of warrants		$ 0.06
Warrant vesting description		Immediately on the Effective Date, 50% of the Warrant shall vest and the remaining 50% shall vest in 18 equal monthly installments beginning on November 30, 2016
Consummation of equity percentage		225.00%
Proceeds from debt financing		$ 1,500,000
Ian T. Bothwell [Member] | Securities Purchase Agreement [Member]
Consummation of equity percentage		25.00%
Proceeds from debt financing	$ 300,000	$ 300,000
Dr. Bruce Werber [Member]
Number of warrant shares issued		31,800,000
Risk free interest rate		1.79%
Expected term		10 years
Expected volatility		152.00%
Expected dividend rate		0.00%
Fair value of warrants		$ 1,879,380
Exercise price of warrants		$ 0.06
Dr. Maria Ines Mitrani [Member]
Number of warrant shares issued		10,000,000
Risk free interest rate		1.79%
Expected term		10 years
Expected volatility		152.00%
Expected dividend rate		0.00%
Fair value of warrants		$ 591,000
Exercise price of warrants		$ 0.06
Minimum [Member]
Risk free interest rate		1.22%	1.50%
Expected volatility		97.00%
Minimum [Member] | During January 2017 and February 2017 [Member]
Risk free interest rate		1.43%
Maximum [Member]
Risk free interest rate		1.57%	1.74%
Expected volatility		100.00%
Maximum [Member] | During January 2017 and February 2017 [Member]
Risk free interest rate		1.45%

Warrants - Schedule of Warrants

Warrants - Schedule of Warrants Granted to Purchase Shares of Common Stock (Details)	Oct. 31, 2016shares
Total	56,850,000
Dr. Bruce Werber [Member]
Total	21,500,000
Ian T. Bothwell [Member]
Total	21,500,000
Dr. Maria Ines Mitrani [Member]
Total	13,850,000

Warrants - Summary of Warrant A

Warrants - Summary of Warrant Activity (Details) - Warrant [Member] - USD ($)	12 Months Ended
	Oct. 31, 2016	Oct. 31, 2015
Number of Shares Outstanding beginning balance	1,008,114
Number of Shares, Granted	729,370	1,008,114
Number of Shares, Exercised
Number of Shares, Expired/Forfeited
Number of Shares Outstanding and exercisable balance	1,737,484	1,008,114
Weighted-average Exercise Price Outstanding beginning balance	$ 0.75
Weighted-average Exercise Price, Granted	0.75	0.75
Weighted-average Exercise Price, Exercised
Weighted-average Exercise Price, Expired/Forfeited
Weighted-average Exercise Price Outstanding and exercisable balance	$ 0.75	$ 0.75
Remaining Contractual Term (years) Outstanding beginning balance	3 years 9 months 11 days
Remaining Contractual Term (years), Granted	4 years	4 years
Remaining Contractual Term (years) Outstanding and exercisable balance	3 years 4 days	3 years 9 months 11 days
Aggregate Intrinsic Value Outstanding beginning balance
Aggregate Intrinsic Value, Granted
Aggregate Intrinsic Value Outstanding and exercisable balance

Commitments and Contingencies46

Commitments and Contingencies (Details Narrative)	Nov. 04, 2016USD ($)$ / sharesshares	Aug. 02, 2015USD ($)shares	Jun. 22, 2015	Oct. 31, 2016USD ($)ft²$ / sharesshares	Oct. 31, 2015USD ($)$ / sharesshares	Jun. 30, 2016USD ($)	Feb. 23, 2016USD ($)	Sep. 03, 2015USD ($)
Warrant to purchase shares of common stock | shares				729,370	1,008,114
Proceeds from debt financing					$ 300
Security deposit				5,000
Minimum monthly lease payments				$ 586,242
Preferred stock, par value | $ / shares				$ 0.001	$ 0.001
Preferred stock, shares authorized | shares				10,000,000	10,000,000
Anu Life Sciences Inc [Member]
Minimum monthly lease payments				$ 486,850
Mint Organics [Member] | Series A Preferred Stock [Member]
Conversion of stock, description				Each share of the Series A Preferred Stock shall automatically convert into 1.5 shares of Class B Common Stock of Mint Organics upon the earlier of (a) the fifth anniversary of the date such share of Series A Preferred Stock was issued; or (b) Mint Organics’ receipt of the necessary licenses and permits required to operate business operations in the medical cannabis industry.
Percentage of outstanding capital stock represents the common stock conversion				45.00%
Preferred stock, par value | $ / shares				$ 0.001
Preferred stock, shares authorized | shares				300
Human Amnion Product [Member]
Commercially available product percentage				25.00%
Securities Purchase Agreement [Member]
Initial carrying amount				$ 333,333
Securities Purchase Agreement [Member] | April 30, 2017 [Member]
Original issue discount and accrued interest				531,826
Five-Year Lease Agreement [Member] | Anu Life Sciences Inc [Member]
Security deposit				37,275
Minimum monthly lease payments				$ 486,850
Laboratory and administrative office space | ft²				3,500
Lease expiration date				Jun. 30, 2022
Conversion, description				(i) $0.15, and (ii) 60% of the lowest daily volume weighed average price in the 20 trading days prior to the conversion Date.
Initial carrying amount				$ 0
Five-Year Lease Agreement [Member] | Anu Life Sciences Inc [Member] | After the 2nd Year Anniversary [Member]
Security deposit				$ 18,638
Consultant [Member]
Percentage of warrant to purchase shares of common stock			4.90%
Two Employees [Member]
Stock issued during period, shares, restricted stock | shares		225,000
Two Employees [Member] | Employment Agreement One[Member] | Net Profit Margin Less Than 35% [Member]
Net monthly sales		$ 50,000
Net profit margin on aggregate sales, percentage		35.00%
Base salary
Two Employees [Member] | Employment Agreement Two [Member] | Net Profit Margin Less Than 35% [Member]
Base salary		6,000
Two Employees [Member] | Employment Agreement Two [Member] | Net Profit Margin Less Than 35% [Member] | Minimum [Member]
Net monthly sales		50,000
Two Employees [Member] | Employment Agreement Two [Member] | Net Profit Margin Less Than 35% [Member] | Maximum [Member]
Net monthly sales		$ 75,000
Net profit margin on aggregate sales, percentage		35.00%
Two Employees [Member] | Employment Agreement Three [Member] | Net Profit Margin Less Than 35% [Member]
Base salary		$ 9,000
Two Employees [Member] | Employment Agreement Three [Member] | Net Profit Margin Less Than 35% [Member] | Minimum [Member]
Net monthly sales		$ 100,000
Net profit margin on aggregate sales, percentage		35.00%
Two Employees [Member] | Employment Agreement Three [Member] | Net Profit Margin Less Than 35% [Member] | Maximum [Member]
Net monthly sales		$ 75,000
Two Employees [Member] | Employment Agreement Four [Member] | Net Profit Margin Less Than 35% [Member]
Base salary		15,000
Two Employees [Member] | Employment Agreement Four [Member] | Net Profit Margin Less Than 35% [Member] | Minimum [Member]
Net monthly sales		$ 100,000
Two Employees [Member] | Employment Agreement Four [Member] | Net Profit Margin Less Than 35% [Member] | Maximum [Member]
Net profit margin on aggregate sales, percentage		35.00%
A. Mitrani [Member] | Executive Employment Agreement [Member]
Base salary	$ 360,000
Ownership percentage	3.00%
Accrued and unpaid signing bonus	$ 100,000
Unpaid expenses, salary and consulting fees	120,000
Dr. Bruce Werber [Member]
Warrant to purchase shares of common stock | shares				31,800,000
Exercise price of warrants | $ / shares				$ 0.06
Dr. Bruce Werber [Member] | Executive Employment Agreement [Member]
Base salary	$ 360,000
Ownership percentage	3.00%
Accrued and unpaid signing bonus	$ 35,000
Exercise price of warrants | $ / shares	$ 0.06
Dr. Bruce Werber [Member] | Executive Employment Agreement [Member] | Maximum [Member]
Warrant to purchase shares of common stock | shares	31,800,000
Dr. Maria Ines Mitrani [Member]
Warrant to purchase shares of common stock | shares				10,000,000
Exercise price of warrants | $ / shares				$ 0.06
Dr. Maria Ines Mitrani [Member] | Executive Employment Agreement [Member]
Base salary	$ 250,000
Ownership percentage	3.00%
Accrued and unpaid signing bonus	$ 50,000
Unpaid expenses, salary and consulting fees	$ 84,000
Exercise price of warrants | $ / shares	$ 0.06
Dr. Maria Ines Mitrani [Member] | Executive Employment Agreement [Member] | March 8, 2017 [Member]
Base salary	$ 300,000
Dr. Maria Ines Mitrani [Member] | Executive Employment Agreement [Member] | Maximum [Member]
Warrant to purchase shares of common stock | shares	10,000,000
Ian T. Bothwell [Member]
Warrant to purchase shares of common stock | shares				31,800,000
Exercise price of warrants | $ / shares				$ 0.06
Consummation of an equity percentage				225.00%
Proceeds from debt financing				$ 1,500,000
Ian T. Bothwell [Member] | Executive Employment Agreement [Member]
Base salary	$ 360,000
Ownership percentage	3.00%
Accrued and unpaid signing bonus	$ 35,000
Exercise price of warrants | $ / shares	$ 0.06
Warrants vesting rights, description	50% of the Bothwell Warrant shall vest and the remaining 50% shall vest in 18 equal monthly installments beginning on November 30, 2016 or until Bothwell no longer remains employed by the Company, whichever is earlier.
Consummation of an equity percentage	25.00%
Proceeds from debt financing	$ 1,500,000
Ian T. Bothwell [Member] | Executive Employment Agreement [Member] | Maximum [Member]
Warrant to purchase shares of common stock | shares	31,800,000
Consummation of an equity percentage	25.00%
Ian T. Bothwell [Member] | Securities Purchase Agreement [Member]
Consummation of an equity percentage				25.00%
Proceeds from debt financing	$ 300,000			$ 300,000
Terrell Suddarth [Member] | Executive Employment Agreement [Member]
Base salary	$ 300,000
Ownership percentage	3.00%
Accrued and unpaid signing bonus	$ 35,000
Exercise price of warrants | $ / shares	$ 0.02
Warrants vesting rights, description	50% of the Suddarth Warrant shall vest and the remaining 50% shall vest in 18 equal monthly installments beginning on March 31, 2017 or until Suddarth no longer remains employed by the Company, whichever is earlier.
Terrell Suddarth [Member] | Executive Employment Agreement [Member] | Human Amnion Product [Member]
Accrued and unpaid signing bonus	$ 35,000
Commercially available product percentage	25.00%
Terrell Suddarth [Member] | Executive Employment Agreement [Member] | Third Available Product [Member]
Accrued and unpaid signing bonus	$ 35,000
Commercially available product percentage	15.00%
Terrell Suddarth [Member] | Executive Employment Agreement [Member] | Fourth Available Product [Member]
Accrued and unpaid signing bonus	$ 35,000
Commercially available product percentage	10.00%
Terrell Suddarth [Member] | Executive Employment Agreement [Member] | Maximum [Member]
Warrant to purchase shares of common stock | shares	23,850,000
Ethan NY [Member]
Security deposit				18,585
Liabilities of discontinued operations				76,000
Estimated reserve for losses on lease				25,905
Impairment loss				5,463
Ethan NY [Member] | Five-Year Lease Agreement [Member]
Security deposit								$ 18,585
Ethan NY [Member] | Five-Year Lease Agreement [Member] | Seven Months Ended June 30, 2016 [Member]
Minimum monthly lease payments						$ 66,500
Ethan NY [Member] | Five-Year Lease Agreement [Member] | Eleven Months Ended June 30, 2016 [Member]
Minimum monthly lease payments				$ 104,785
Ethan NY [Member] | Five-Year Lease Agreement [Member] | December 2015 through October 2020 [Member]
Minimum monthly lease payments						$ 9,500
Ethan NY [Member] | Distribution Agreement [Member]
Source's non-payment outstanding							$ 4,815

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Lease Payments (Details)	Oct. 31, 2016USD ($)
Total	$ 586,242
Ethan NY [Member]
2,016	104,785
2,017	117,714
2,018	121,245
2,019	124,882
2,020	117,616
2,021
Total	586,242
Anu Life Sciences Inc [Member]
2,017	23,007
2,018	90,020
2,019	94,022
2,020	102,877
2,021	105,455
Thereafter	71,470
Total	$ 486,850

Mint Organics (Details Narrativ

Mint Organics (Details Narrative) - USD ($)	May 28, 2015	Feb. 19, 2015	Oct. 31, 2016	Oct. 31, 2015
Proceeds from debt financing				$ 300
Common stock, shares authorized			750,000,000	750,000,000
Common stock, par value			$ 0.001	$ 0.001
Preferred stock, par value			$ 0.001	$ 0.001
Preferred stock, shares authorized			10,000,000	10,000,000
Number of preferred stock issued			0	0
Number of common stock issued			104,214,982	99,198,114
Proceeds from sale of units	$ 25,000	$ 25,000	$ 457,279	$ 496,200
Maximum [Member]
Common stock, shares authorized			250,000,000
Common stock, par value			$ 0.001
Taddeo [Member]
Base salary			$ 180,000
Taddeo [Member] | Maximum [Member]
Base salary			$ 250,000
February 28, 2017 [Member]
Number of common stock warrants exercisable			150,000
Exercise price of warrants			$ 0.15
February 28, 2017 [Member] | Class A Voting Common Stock [Member] | Mint Organics Florida, Inc [Member]
Common stock, par value			$ 0.001
Number of common stock issued			2,125
Fair consideration for the initial issuance of common stock			$ 0.001
February 28, 2017 [Member] | Series A Convertible Preferred Stock [Member]
Preferred stock, par value			$ 0.001
Preferred stock, shares authorized			300
Preferred stock, stated value			$ 1,000
Conversion of stock, description			The amount of each share of the Series A Preferred Stock shall automatically convert into 1.5 shares of Class B Common Stock of Mint Organics upon the earlier of (a) the fifth anniversary of the date such share of Series A Preferred Stock was issued; or (b) Mint Organics’ receipt of the necessary licenses and permits required to operate business operations in the medical cannabis industry.
Percentage of outstanding capital stock represents the common stock conversion			45.00%
February 28, 2017 [Member] | Series A Preferred Stock [Member]
Number of preferred stock issued			150
May 1, 2017 [Member]
Ownership percentage			3.00%
March 17, 2017 [Member] | Class B Non-Voting Common Stock [Member] | Mint Organics Florida, Inc [Member]
Ownership percentage			10.00%
Conversion of stock, amount			$ 1,000,000
Conversion of stock, shares converted			212.5
April 6, 2017 [Member] | Mint Organics Florida, Inc [Member]
Proceeds from sale of units			$ 100,000
Number of units sold, description			Mint Organics received proceeds of $100,000 in connection with the sale of 21.25 units to an investor in connection with the offering.
Participation Agreement [Member] | February 14, 2017 [Member]
Investments			$ 150,000
Ownership percentage			55.00%
Proceeds from debt financing			$ 150,000
Participation Agreement [Member] | February 14, 2017 [Member] | Class A Voting Common Stock [Member]
Common stock, shares authorized			1,000
Common stock, par value			$ 0.001
Participation Agreement [Member] | February 14, 2017 [Member] | Class A Voting Common Stock [Member] | Biotech Products Services and Research [Member]
Ownership percentage			100.00%
Common stock, shares authorized			550
Participation Agreement [Member] | February 14, 2017 [Member] | Class A Voting Common Stock [Member] | Mint Organics Florida, Inc [Member]
Common stock, shares authorized			10,000
Common stock, par value			$ 0.001
Participation Agreement [Member] | February 14, 2017 [Member] | Class B Non-Voting Common Stock [Member]
Common stock, shares authorized			1,000
Common stock, par value			$ 0.001
Participation Agreement [Member] | February 14, 2017 [Member] | Class B Non-Voting Common Stock [Member] | Mint Organics Florida, Inc [Member]
Common stock, shares authorized			10,000
Common stock, par value			$ 0.001
Participation Agreement [Member] | February 14, 2017 [Member] | Preferred Stock [Member]
Preferred stock, par value			$ 0.001
Preferred stock, shares authorized			1,000
Taddeo Agreement [Member]
Accrued and unpaid signing bonus			$ 25,000
Number of unregistered common stock shares granted			1,000,000
Consulting Agreement [Member] | February 15, 2017 [Member] | Mint Organics Florida, Inc [Member]
Payments required to pay as monthly fee			$ 7,500
Equity interest, percent			3.00%
Number of shares granted to receive equity interest, description			Consulting Firm will be entitled to receive a 3% equity interest in Mint Organics Florida through granting of 63.75 shares of Class B Common Stock of Mint Organics Florida.

Mint Organics - Schedule of War

Mint Organics - Schedule of Warrants Issued to Purchase Common Stock for Executives (Details)	12 Months Ended
	Oct. 31, 2016$ / sharesshares
Warrants, Total	237
Albert Mitrani [Member]
Warrants, Total	79
Exercise Price | $ / shares	$ 0.001
Ian T. Bothwell [Member]
Warrants, Total	79
Exercise Price | $ / shares	$ 0.001
Dr. Maria I. Mitrani [Member]
Warrants, Total	79
Exercise Price | $ / shares	$ 0.001

Discontinued Operations (Detail

Discontinued Operations (Details Narrative)	Oct. 30, 2015USD ($)
Stock Purchase Agreement [Member] | John Goodhew [Member]
Purchase price for shares sold	$ 10

Discontinued Operations - Sched

Discontinued Operations - Schedule of Assets and Liabilities (Details) - USD ($)	Oct. 31, 2016	Oct. 31, 2015
Assets, total		$ 89,353
Liabilities, total	125,851	9,771
Ethan NY [Member]
Cash		61,730
Inventories		1,608
Prepaid Expenses		1,250
Security Deposits		18,585
Property, Plant and Equipment, net		6,180
Assets, total		89,353
Accounts Payable	94,835
Accrued Expenses	31,016
Deferred Rent		9,771
Liabilities, total	$ 125,851	$ 9,771

Discontinued Operations - Sch52

Discontinued Operations - Schedule of Loss on Disposal (Details) - Bespoke [Member] - USD ($)	12 Months Ended
	Oct. 31, 2016	Oct. 31, 2015
Cash received		$ 10
Total consideration		10
Bespoke's net assets		(5,679)
Loss on disposal of Bespoke		$ (5,669)

Discontinued Operations - Summa

Discontinued Operations - Summary of Revenues and Expenses, Net and Net Income of Discontinued Operations (Details) - USD ($)	12 Months Ended
	Oct. 31, 2016	Oct. 31, 2015
Total Revenues	$ 68,598	$ 54,008
Total Expenses, net	265,753	42,384
Net income (loss) from discontinued operations	(197,155)	5,955
Bespoke [Member]
Total Revenues		54,008
Total Expenses, net		23,812
Loss on disposal of Bespoke		(5,669)
Net income (loss) from discontinued operations		24,527
Ethan NY [Member]
Total Revenues	68,598
Total Expenses, net	265,753	18,572
Net income (loss) from discontinued operations	$ (197,155)	$ (18,572)